This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Implicit parasitic Sepsis
AB1_SEPSIS_PARAS_IMPL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditions
|
65788 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
190 |
4. Check minimum number of eventsNone |
190 |
5. Include endpointsNone |
190 |
6. Filter based on genotype QC (FinnGen only) |
185 |
Control definitions (FinnGen only)
- Control exclude
- AB1_SEPSIS_EXPLICIT, AB1_SEPSIS_IMPLICIT
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Implicit parasitic Sepsis
based on the number of shared cases.
Similar with more cases:
- Implicit parasitic Sepsis, including avohilmo
- Implicit Sepsis
- Implicit Sepsis, including avohilmo
- Condition for Implicit Sepsis (Organ dysfunction codes)
- Condition for Implicit Sepsis (Organ dysfunction codes), including avohilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 185 | 103 | 82 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 53.25 | 50.84 | 56.28 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 190
- Matched controls
- 1900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
R55
ICD-10 Finland
Syncope and collapse
30.3
115.9
91
56
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
11.4
45.8
56
67
AA1AD
NOMESCO Finland
CT of head and brain
5.1
27.6
98
330
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
5.2
25.4
72
200
A07.8
ICD-10 Finland
Other specified protozoal intestinal diseases
273.0
24.2
24
*
N17.9
ICD-10 Finland
Acute renal failure, unspecified
143.1
24.2
25
*
A06.9
ICD-10 Finland
Amoebiasis, unspecified
+∞
20.2
19
*
A07.1
ICD-10 Finland
Giardiasis [lambliasis]
209.9
18.9
19
*
R50.9
ICD-10 Finland
Fever, unspecified
4.6
18.2
54
152
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.3
18.1
62
194
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.8
17.6
126
646
R51.80
ICD-10 Finland
Headache
4.0
16.0
58
188
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
15.7
68
248
P01AB01
ATC
metronidazole; oral, rectal
3.4
15.3
107
525
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
15.1
81
338
J01MA12
ATC
levofloxacin; systemic
3.7
14.8
60
209
D64.9
ICD-10 Finland
Anaemia, unspecified
4.6
14.2
38
97
XF400
NOMESCO Finland
ECG with 12 standard connections
3.8
13.8
53
177
A07.9
ICD-10 Finland
Protozoal intestinal disease, unspecified
150.3
13.6
14
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.7
13.4
52
175
C03CA01
ATC
furosemide; systemic
3.2
13.3
81
360
R06.0
ICD-10 Finland
Dyspnoea
3.1
12.9
80
358
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
12.7
42
126
A41.9
ICD-10 Finland
Sepsis, unspecified
138.8
12.6
13
*
J01FF01
ATC
clindamycin; systemic
3.1
12.4
72
309
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
5.1
12.4
28
62
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.1
12.3
39
113
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.7
11.6
23
45
H02AB06
ATC
prednisolone; systemic
2.9
11.4
111
625
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.3
11.4
55
211
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.5
11.0
45
155
A28
ICPC
Limited function/disability NOS
3.3
10.8
50
186
N05BA01
ATC
diazepam; systemic, rectal
3.7
10.8
40
129
E0000UV, ,
ATC
2.7
10.6
100
549
A06.0
ICD-10 Finland
Acute amoebic dysentery
+∞
10.5
10
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
10.4
89
464
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.9
10.3
66
295
A06AC01
ATC
ispaghula (psylla seeds); oral
2.9
10.3
67
302
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.4
10.2
44
156
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.5
10.2
41
139
A10AB05
ATC
insulin aspart; parenteral
4.5
10.1
26
64
W19
ICD-10 Finland
Unspecified fall
4.0
10.0
31
88
UJF32
NOMESCO Finland
Coloscopy
2.8
9.9
65
294
Z2221
NOMESCO Finland
Medical doctor
2.8
9.8
70
331
JN4AD
NOMESCO Finland
Body CT examination
3.7
9.8
35
110
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.7
9.8
35
110
A04
ICPC
Weakness/tiredness general
3.2
9.7
47
179
E86
ICD-10 Finland
Volume depletion
13.3
9.6
16
13
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
5.1
9.6
21
45
UJF30
NOMESCO Finland
Ileoscopy through colon
3.7
9.5
34
107
B54
ICD-10 Finland
Unspecified malaria
+∞
9.4
9
*
1369X
ICD-9 Finland
Other and unspecified infectious and parasitic diseases, Unspecified infectious and parasitic diseases
+∞
9.4
9
*
H02AB07
ATC
prednisone; oral
3.6
9.4
35
113
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
9.2
54
229
J01MA02
ATC
ciprofloxacin; systemic
2.5
8.9
89
491
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
2.9
8.9
50
207
R42
ICD-10 Finland
Dizziness and giddiness
2.7
8.8
61
281
WX002
NOMESCO Finland
Sedation and analgesia
2.9
8.8
51
214
L04AA01
ATC
[U] ciclosporin
52.5
8.8
10
*
N02AA05
ATC
oxycodone; systemic
2.9
8.7
49
202
L28
ICPC
Limited function/disability (L)
2.9
8.7
49
202
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
4.6
8.7
22
53
C03DA01
ATC
spironolactone; oral
3.4
8.7
34
113
R4110
NOMESCO Finland
Physiotherapy
2.6
8.7
72
363
J01MA06
ATC
norfloxacin; oral
3.2
8.6
38
136
127
Kela drug reimbursment
Transplant complication
29.0
8.6
11
*
A02BC05
ATC
esomeprazole; systemic
2.5
8.4
91
517
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.6
8.4
21
50
N17
ICPC
Vertigo/dizziness
3.2
8.4
38
138
R5140
NOMESCO Finland
Monitoring the use of the aid
3.3
8.4
35
121
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
+∞
8.4
8
*
R53
ICD-10 Finland
Malaise and fatigue
2.6
8.3
68
339
N05CF01
ATC
zopiclone; oral
2.5
8.3
77
408
N05CD07
ATC
temazepam; oral
3.3
8.3
35
122
A10AC01
ATC
insulin (human); parenteral
4.2
8.2
23
60
I50.9
ICD-10 Finland
Heart failure, unspecified
3.1
8.2
38
140
A10AE04
ATC
insulin glargine; parenteral
3.7
8.2
28
85
103
Kela drug reimbursment
Diabetes, insulin-treated
2.6
8.1
63
307
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
8.0
76
405
N30.0
ICD-10 Finland
Acute cystitis
3.0
8.0
42
166
A06AD11
ATC
lactulose; oral
3.1
8.0
37
136
Z03
ICD-10 Finland
Medical observation and evaluation for suspected diseases and conditions, ruled out
3.5
7.9
29
92
R06AE07
ATC
cetirizine; oral
2.4
7.9
97
579
J96.1
ICD-10 Finland
Chronic respiratory failure
46.9
7.8
9
*
S06.0
ICD-10 Finland
Concussion
3.2
7.8
34
121
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.7
7.7
51
228
A02BC01
ATC
omeprazole; systemic
2.5
7.7
64
321
N06AX21
ATC
duloxetine; oral
3.2
7.7
34
122
FPE20
NOMESCO Finland
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
7.0
7.6
18
28
H02AB04
ATC
methylprednisolone; systemic
3.0
7.6
39
152
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.0
7.6
23
64
A11
ICPC
Chest pain NOS
3.5
7.5
28
90
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
7.4
7.5
17
25
Z3226
NOMESCO Finland
Physiotherapist
2.7
7.5
49
218
B50.9
ICD-10 Finland
Plasmodium falciparum malaria, unspecified
83.2
7.5
8
*
H32.0*B58.0
ICD-10 Finland
Toxoplasma chorioretinitis
83.2
7.5
8
*
R07.4
ICD-10 Finland
Chest pain, unspecified
2.4
7.5
69
362
R11
ICD-10 Finland
Nausea and vomiting
3.5
7.5
27
85
B01AA03
ATC
warfarin; systemic
2.7
7.5
47
205
SPAT1229
SPAT
Assessment of need for aid
4.0
7.4
22
60
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.7
7.4
25
75
XF404
NOMESCO Finland
Ambulatory ECG
3.7
7.4
25
75
N05CF02
ATC
zolpidem; oral
2.8
7.4
44
186
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
4.6
7.4
18
42
N05AH04
ATC
quetiapine; oral
2.7
7.4
45
193
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
16.6
7.3
11
7
D06
ICPC
Abdominal pain localized other
3.6
7.3
26
81
ZXE10
NOMESCO Finland
More than one and less than three hours
2.3
7.3
80
452
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.6
7.3
25
76
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.0
7.2
36
138
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
21.0
7.2
10
5
N06CA01
ATC
amitriptyline and psycholeptics; systemic
3.3
7.2
29
98
D11
ICPC
Diarrhoea
3.0
7.1
36
139
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.7
7.1
17
39
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.7
7.1
24
72
J45.9
ICD-10 Finland
Asthma, unspecified
2.6
7.1
48
217
N06AA09
ATC
amitriptyline; systemic
3.3
7.1
29
99
A10AE05
ATC
insulin detemir; parenteral
4.4
7.0
18
44
SPAT1255
SPAT
Intravenous administration of medicine
4.4
7.0
18
44
XF402
NOMESCO Finland
ECG with work load test
3.2
6.9
29
100
ZX120
NOMESCO Finland
Intravenous
3.3
6.9
28
95
C07AB07
ATC
bisoprolol; oral
2.2
6.9
107
694
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
6.9
6.8
16
25
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.2
6.8
28
96
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
3.2
6.8
28
96
C07AB02
ATC
metoprolol; systemic
2.6
6.7
48
222
C07AG02
ATC
carvedilol; oral
3.9
6.7
20
55
H04AA01
ATC
glucagon; nasal, parenteral
9.2
6.7
13
15
N03AX09
ATC
lamotrigine; oral
5.7
6.7
18
34
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.7
6.6
22
65
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.3
6.6
27
92
D20
ICPC
Mouth/tongue/lip symptom/complaint
4.0
6.5
19
51
L04AA06
ATC
mycophenolic acid; systemic
15.0
6.5
10
7
Z94.0
ICD-10 Finland
Kidney transplant status
72.2
6.5
7
*
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
6.4
6.5
16
27
E000001, ,
ATC
2.5
6.5
48
226
SPAT1262
SPAT
Handing over of treatment supplies
2.7
6.4
39
166
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.4
6.4
55
277
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.6
6.4
44
200
N02AX02
ATC
tramadol; systemic, rectal
2.2
6.3
91
566
A02BC03
ATC
lansoprazole; oral
2.3
6.3
65
353
C01DA02
ATC
glyceryl trinitrate; oral, oral aerosol, sublingual, transdermal
2.5
6.3
47
221
A29
ICPC
General symptom/complaint other
2.8
6.3
35
142
N03AX16
ATC
[U] pregabalin
2.4
6.3
54
271
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
6.3
6
*
J96.0
ICD-10 Finland
Acute respiratory failure
+∞
6.3
6
*
B58.9
ICD-10 Finland
Toxoplasmosis, unspecified
+∞
6.3
6
*
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
6.2
35
143
Z71.8
ICD-10 Finland
Other specified counselling
2.2
6.2
77
451
N06AX11
ATC
mirtazapine; oral
2.2
6.2
77
451
I20.99
ICD-10 Finland
Angina pectoris, unspecified
3.7
6.2
20
58
XW000
NOMESCO Finland
Bone marrow biopsy
5.6
6.2
17
33
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
10.5
6.1
11
11
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
6.1
38
164
K59.09
ICD-10 Finland
Constipation, unspecified
3.6
6.1
21
64
I50.0
ICD-10 Finland
Congestive heart failure
3.7
6.1
20
59
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Internal Medicine
11 [38004456]
11 [38004456]
1.4e+00
2.0e+00
2.9e+00
—
2.6e+00
1.8e+00
1.7e+00
cases:44.63%
controls:17.28%
cases:31.64%
controls:5.72%
cases:16.38%
controls:1.02%
—
—
cases:15.25%
controls:1.31%
cases:31.18%
controls:6.77%
cases:51.95%
controls:16.96%
79
305
98
1460
56
101
121
1664
29
18
148
1747
—
27
23
150
1739
53
117
117
1610
80
268
74
1312
Outpatient Visit
OP [9202]
OP [9202]
9.3e-01
8.3e-01
1.4e+00
4.1e+00
1.7e+00
1.1e+00
1.2e+00
cases:77.97%
controls:58.19%
cases:57.63%
controls:37.28%
cases:25.99%
controls:8.33%
cases:29.94%
controls:0.68%
cases:31.64%
controls:8.06%
cases:67.65%
controls:40.01%
cases:87.01%
controls:67.78%
138
1027
39
738
102
658
75
1107
46
147
131
1618
53
12
124
1753
56
142
121
1620
115
691
55
1036
134
1071
20
509
Emergency Room Visit
ER [9203]
ER [9203]
9.5e-01
1.9e+00
3.1e+00
—
1.6e+00
1.9e+00
1.2e+00
cases:47.46%
controls:25.95%
cases:33.33%
controls:7.14%
cases:18.08%
controls:0.96%
—
—
cases:5.65%
controls:1.19%
cases:36.47%
controls:8.22%
cases:53.25%
controls:25.06%
84
458
93
1307
59
126
118
1639
32
17
145
1748
—
10
21
167
1741
62
142
108
1585
82
396
72
1184
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
1.1e+00
2.5e+00
—
1.0e+50
3.1e+00
2.3e+00
1.2e+00
cases:12.43%
controls:4.36%
cases:13.56%
controls:1.30%
—
—
cases:2.82%
controls:0.00%
cases:7.34%
controls:0.34%
cases:11.76%
controls:1.33%
cases:14.94%
controls:5.19%
22
77
155
1688
24
23
153
1742
—
5
0
172
1765
13
6
164
1756
20
23
150
1704
23
82
131
1498
Inpatient Hospital
21 [8717]
21 [8717]
7.6e-01
1.4e+00
2.4e+00
—
2.8e+00
1.6e+00
1.0e+00
cases:44.07%
controls:26.91%
cases:28.25%
controls:8.50%
cases:11.30%
controls:1.19%
—
—
cases:13.56%
controls:0.96%
cases:31.76%
controls:8.40%
cases:50.00%
controls:26.46%
78
475
99
1290
50
150
127
1615
20
21
157
1744
—
24
17
153
1745
54
145
116
1582
77
418
77
1162
General Practice
1 [38004446]
1 [38004446]
7.4e-01
1.3e+00
2.9e+00
1.0e+50
2.8e+00
1.5e+00
1.3e+00
cases:16.38%
controls:8.56%
cases:11.30%
controls:3.23%
cases:5.65%
controls:0.34%
cases:6.21%
controls:0.00%
cases:4.52%
controls:0.28%
cases:14.71%
controls:3.76%
cases:32.47%
controls:12.03%
29
151
148
1614
20
57
157
1708
10
6
167
1759
11
0
166
1765
8
5
169
1757
25
65
145
1662
50
190
104
1390
Psychiatry
26 [38004469]
26 [38004469]
1.8e+00
1.8e+00
1.9e+00
—
—
2.2e+00
1.6e+00
cases:14.12%
controls:2.55%
cases:6.78%
controls:1.13%
cases:3.95%
controls:0.62%
—
—
—
—
cases:8.82%
controls:1.04%
cases:16.88%
controls:3.99%
25
45
152
1720
12
20
165
1745
7
11
170
1754
—
—
15
18
155
1709
26
63
128
1517
Outpatient Hospital
22 [8756]
22 [8756]
7.6e-01
1.3e+00
2.3e+00
1.0e+50
2.6e+00
1.1e+00
9.6e-01
cases:33.90%
controls:19.38%
cases:18.64%
controls:5.89%
cases:6.21%
controls:0.68%
cases:7.34%
controls:0.00%
cases:10.17%
controls:0.79%
cases:16.47%
controls:6.25%
cases:40.91%
controls:20.95%
60
342
117
1423
33
104
144
1661
11
12
166
1753
13
0
164
1765
18
14
159
1748
28
108
142
1619
63
331
91
1249
Gastroenterology
10 [38004455]
10 [38004455]
1.4e+00
2.1e+00
2.6e+00
1.0e+50
2.3e+00
2.4e+00
9.5e-01
cases:8.47%
controls:2.21%
cases:8.47%
controls:1.13%
cases:4.52%
controls:0.34%
cases:5.08%
controls:0.00%
cases:2.82%
controls:0.28%
cases:12.94%
controls:1.33%
cases:9.09%
controls:3.73%
15
39
162
1726
15
20
162
1745
8
6
169
1759
9
0
168
1765
5
5
172
1757
22
23
148
1704
14
59
140
1521
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
7.9e-01
2.0e+00
2.7e+00
—
2.2e+00
1.6e+00
7.9e-01
cases:9.60%
controls:4.59%
cases:11.86%
controls:1.87%
cases:3.95%
controls:0.28%
—
—
cases:4.52%
controls:0.51%
cases:11.18%
controls:2.55%
cases:16.23%
controls:8.10%
17
81
160
1684
21
33
156
1732
7
5
170
1760
—
8
9
169
1753
19
44
151
1683
25
128
129
1452
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
6.3e-01
1.6e+00
2.6e+00
—
2.0e+00
1.5e+00
7.9e-01
cases:10.17%
controls:5.67%
cases:11.86%
controls:2.66%
cases:6.78%
controls:0.51%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:2.78%
cases:14.94%
controls:7.41%
18
100
159
1665
21
47
156
1718
12
9
165
1756
—
7
10
170
1752
19
48
151
1679
23
117
131
1463
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
5.7e-01
1.5e+00
2.6e+00
—
2.0e+00
1.5e+00
7.9e-01
cases:9.60%
controls:5.67%
cases:11.30%
controls:2.66%
cases:6.78%
controls:0.51%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:2.78%
cases:14.94%
controls:7.41%
17
100
160
1665
20
47
157
1718
12
9
165
1756
—
7
10
170
1752
19
48
151
1679
23
117
131
1463
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
5.8e-01
1.5e+00
2.6e+00
—
2.0e+00
1.5e+00
7.6e-01
cases:9.60%
controls:5.61%
cases:10.73%
controls:2.66%
cases:6.78%
controls:0.51%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:2.78%
cases:14.94%
controls:7.59%
17
99
160
1666
19
47
158
1718
12
9
165
1756
—
7
10
170
1752
19
48
151
1679
23
120
131
1460
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
6.2e-01
1.6e+00
2.5e+00
—
2.0e+00
1.4e+00
7.1e-01
cases:10.17%
controls:5.72%
cases:11.86%
controls:2.72%
cases:6.78%
controls:0.57%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:2.95%
cases:14.94%
controls:7.91%
18
101
159
1664
21
48
156
1717
12
10
165
1755
—
7
10
170
1752
19
51
151
1676
23
125
131
1455
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
9.5e-01
1.4e+00
1.6e+00
—
1.4e+00
1.2e+00
8.6e-01
cases:24.86%
controls:11.39%
cases:20.90%
controls:6.23%
cases:6.21%
controls:1.36%
—
—
cases:5.65%
controls:1.48%
cases:18.82%
controls:6.31%
cases:28.57%
controls:14.49%
44
201
133
1564
37
110
140
1655
11
24
166
1741
—
10
26
167
1736
32
109
138
1618
44
229
110
1351
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
5.9e-01
1.6e+00
2.2e+00
—
2.0e+00
1.5e+00
7.6e-01
cases:9.60%
controls:5.55%
cases:11.30%
controls:2.55%
cases:5.08%
controls:0.57%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:2.72%
cases:14.94%
controls:7.59%
17
98
160
1667
20
45
157
1720
9
10
168
1755
—
7
10
170
1752
19
47
151
1680
23
120
131
1460
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
5.3e-01
1.2e+00
2.1e+00
—
2.0e+00
1.1e+00
8.2e-01
cases:12.99%
controls:8.10%
cases:11.30%
controls:3.68%
cases:5.08%
controls:0.68%
—
—
cases:4.52%
controls:0.62%
cases:11.76%
controls:4.28%
cases:21.43%
controls:10.76%
23
143
154
1622
20
65
157
1700
9
12
168
1753
—
8
11
169
1751
20
74
150
1653
33
170
121
1410
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
5.2e-01
1.3e+00
2.4e+00
1.0e+50
2.1e+00
1.4e+00
6.8e-01
cases:10.17%
controls:6.29%
cases:11.30%
controls:3.23%
cases:6.78%
controls:0.68%
cases:2.82%
controls:0.00%
cases:4.52%
controls:0.57%
cases:11.76%
controls:3.30%
cases:16.88%
controls:9.37%
18
111
159
1654
20
57
157
1708
12
12
165
1753
5
0
172
1765
8
10
169
1752
20
57
150
1670
26
148
128
1432
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
5.8e-01
1.4e+00
2.4e+00
—
2.0e+00
1.3e+00
7.1e-01
cases:10.17%
controls:5.95%
cases:11.30%
controls:2.95%
cases:6.21%
controls:0.62%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:3.24%
cases:16.23%
controls:8.73%
18
105
159
1660
20
52
157
1713
11
11
166
1754
—
7
10
170
1752
19
56
151
1671
25
138
129
1442
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
7.8e-01
1.3e+00
3.0e+00
—
1.9e+00
1.7e+00
1.0e+00
cases:7.34%
controls:3.51%
cases:7.34%
controls:2.10%
cases:6.21%
controls:0.34%
—
—
cases:2.82%
controls:0.45%
cases:9.41%
controls:1.85%
cases:12.99%
controls:5.13%
13
62
164
1703
13
37
164
1728
11
6
166
1759
—
5
8
172
1754
16
32
154
1695
20
81
134
1499
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
5.6e-01
1.4e+00
2.3e+00
—
2.0e+00
1.3e+00
6.7e-01
cases:10.17%
controls:6.06%
cases:11.30%
controls:2.95%
cases:5.65%
controls:0.62%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:3.24%
cases:16.23%
controls:8.99%
18
107
159
1658
20
52
157
1713
10
11
167
1754
—
7
10
170
1752
19
56
151
1671
25
142
129
1438
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
1.2e+00
2.0e+00
—
—
—
2.2e+00
1.7e+00
cases:7.91%
controls:2.55%
cases:6.78%
controls:1.02%
—
—
—
—
—
—
cases:7.65%
controls:0.93%
cases:10.39%
controls:2.15%
14
45
163
1720
12
18
165
1747
—
—
—
13
16
157
1711
16
34
138
1546
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
5.2e-01
1.4e+00
2.3e+00
—
2.0e+00
1.3e+00
6.4e-01
cases:10.17%
controls:6.29%
cases:11.30%
controls:3.06%
cases:6.21%
controls:0.68%
—
—
cases:3.95%
controls:0.57%
cases:11.18%
controls:3.42%
cases:16.23%
controls:9.24%
18
111
159
1654
20
54
157
1711
11
12
166
1753
—
7
10
170
1752
19
59
151
1668
25
146
129
1434
Ophthalmology
18 [38004463]
18 [38004463]
7.9e-01
1.1e+00
1.2e+00
—
2.9e+00
1.1e+00
8.6e-01
cases:22.03%
controls:11.39%
cases:13.56%
controls:4.82%
cases:4.52%
controls:1.36%
—
—
cases:7.34%
controls:0.45%
cases:15.29%
controls:5.56%
cases:28.57%
controls:14.43%
39
201
138
1564
24
85
153
1680
8
24
169
1741
—
13
8
164
1754
26
96
144
1631
44
228
110
1352
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
—
2.7e+00
—
—
—
2.2e+00
1.9e+00
—
—
cases:3.95%
controls:0.28%
—
—
—
—
—
—
cases:3.53%
controls:0.41%
cases:5.19%
controls:0.82%
—
7
5
170
1760
—
—
—
6
7
164
1720
8
13
146
1567
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
3.8e-01
1.2e+00
2.3e+00
—
1.8e+00
1.3e+00
6.3e-01
cases:10.17%
controls:7.20%
cases:11.30%
controls:3.80%
cases:6.78%
controls:0.74%
—
—
cases:4.52%
controls:0.79%
cases:12.35%
controls:3.82%
cases:17.53%
controls:10.13%
18
127
159
1638
20
67
157
1698
12
13
165
1752
—
8
14
169
1748
21
66
149
1661
27
160
127
1420
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-6.5e-02
2.6e-01
1.6e+00
3.8e+00
1.0e+00
2.4e-01
1.3e-01
cases:22.03%
controls:23.17%
cases:25.99%
controls:21.25%
cases:25.42%
controls:6.57%
cases:11.30%
controls:0.28%
cases:15.25%
controls:5.96%
cases:27.65%
controls:23.10%
cases:38.31%
controls:35.25%
39
409
138
1356
46
375
131
1390
45
116
132
1649
20
5
157
1760
27
105
150
1657
47
399
123
1328
59
557
95
1023
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.2e-01
8.8e-01
2.7e+00
—
2.1e+00
7.5e-01
4.6e-01
cases:17.51%
controls:15.86%
cases:20.90%
controls:9.92%
cases:15.82%
controls:1.30%
—
—
cases:12.43%
controls:1.70%
cases:21.18%
controls:11.29%
cases:34.42%
controls:24.87%
31
280
146
1485
37
175
140
1590
28
23
149
1742
—
22
30
155
1732
36
195
134
1532
53
393
101
1187
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
1.1e+00
2.5e+00
—
—
—
2.1e+00
1.7e+00
cases:3.95%
controls:1.30%
cases:3.95%
controls:0.34%
—
—
—
—
—
—
cases:4.71%
controls:0.58%
cases:8.44%
controls:1.71%
7
23
170
1742
7
6
170
1759
—
—
—
8
10
162
1717
13
27
141
1553
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.0e+00
1.9e+00
—
—
—
1.8e+00
1.5e+00
cases:11.86%
controls:4.53%
cases:9.60%
controls:1.53%
—
—
—
—
—
—
cases:8.24%
controls:1.51%
cases:22.08%
controls:5.76%
21
80
156
1685
17
27
160
1738
—
—
—
14
26
156
1701
34
91
120
1489
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.3e+00
2.2e+00
—
—
—
1.6e+00
1.1e+00
cases:19.21%
controls:6.01%
cases:11.86%
controls:1.47%
—
—
—
—
—
—
cases:10.00%
controls:2.20%
cases:16.88%
controls:6.33%
34
106
143
1659
21
26
156
1739
—
—
—
17
38
153
1689
26
100
128
1480
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
1.3e+00
1.8e+00
—
—
—
1.7e+00
1.4e+00
cases:7.91%
controls:2.21%
cases:5.08%
controls:0.91%
—
—
—
—
—
—
cases:5.29%
controls:0.98%
cases:11.04%
controls:3.10%
14
39
163
1726
9
16
168
1749
—
—
—
9
17
161
1710
17
49
137
1531
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
4.6e-01
1.3e+00
2.2e+00
—
1.5e+00
1.1e+00
3.7e-01
cases:15.25%
controls:10.20%
cases:15.82%
controls:4.70%
cases:9.04%
controls:1.13%
—
—
cases:5.08%
controls:1.14%
cases:15.29%
controls:5.73%
cases:20.78%
controls:15.32%
27
180
150
1585
28
83
149
1682
16
20
161
1745
—
9
20
168
1742
26
99
144
1628
32
242
122
1338
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
1.3e+00
1.5e+00
—
—
1.2e+00
1.6e+00
1.4e+00
cases:12.43%
controls:3.57%
cases:10.73%
controls:2.72%
—
—
—
—
cases:3.39%
controls:1.02%
cases:12.94%
controls:2.84%
cases:19.48%
controls:5.38%
22
63
155
1702
19
48
158
1717
—
—
6
18
171
1744
22
49
148
1678
30
85
124
1495
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
1.7e+00
1.9e+00
—
—
—
2.3e+00
1.8e+00
cases:6.78%
controls:1.36%
cases:3.39%
controls:0.51%
—
—
—
—
—
—
cases:2.94%
controls:0.29%
cases:5.19%
controls:0.89%
12
24
165
1741
6
9
171
1756
—
—
—
5
5
165
1722
8
14
146
1566
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.3e+00
2.2e+00
—
—
—
1.8e+00
1.6e+00
cases:2.82%
controls:0.79%
cases:3.39%
controls:0.40%
—
—
—
—
—
—
cases:4.12%
controls:0.69%
cases:7.79%
controls:1.71%
5
14
172
1751
6
7
171
1758
—
—
—
7
12
163
1715
12
27
142
1553
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
—
2.0e+00
—
—
—
2.1e+00
1.3e+00
—
—
cases:4.52%
controls:0.62%
—
—
—
—
—
—
cases:4.71%
controls:0.58%
cases:7.79%
controls:2.22%
—
8
11
169
1754
—
—
—
8
10
162
1717
12
35
142
1545
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
2.9e-01
7.6e-01
2.6e+00
—
1.6e+00
1.2e+00
4.5e-01
cases:13.56%
controls:10.54%
cases:10.73%
controls:5.33%
cases:7.91%
controls:0.62%
—
—
cases:5.08%
controls:1.02%
cases:14.12%
controls:4.75%
cases:22.08%
controls:15.32%
24
186
153
1579
19
94
158
1671
14
11
163
1754
—
9
18
168
1744
24
82
146
1645
34
242
120
1338
Pulmonary Disease
29 [38004472]
29 [38004472]
9.8e-01
1.4e+00
1.6e+00
—
1.6e+00
1.7e+00
1.2e+00
cases:14.12%
controls:5.84%
cases:9.60%
controls:2.55%
cases:3.39%
controls:0.74%
—
—
cases:2.82%
controls:0.57%
cases:14.12%
controls:2.78%
cases:20.78%
controls:7.03%
25
103
152
1662
17
45
160
1720
6
13
171
1752
—
5
10
172
1752
24
48
146
1679
32
111
122
1469
Neurology
13 [38004458]
13 [38004458]
1.1e+00
1.3e+00
—
—
—
1.6e+00
1.3e+00
cases:18.08%
controls:6.97%
cases:10.73%
controls:3.06%
—
—
—
—
—
—
cases:12.94%
controls:2.90%
cases:24.03%
controls:7.72%
32
123
145
1642
19
54
158
1711
—
—
—
22
50
148
1677
37
122
117
1458
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
7.0e-01
1.7e+00
2.5e+00
—
—
1.2e+00
7.8e-01
cases:7.34%
controls:3.80%
cases:8.47%
controls:1.70%
cases:3.39%
controls:0.28%
—
—
—
—
cases:8.24%
controls:2.72%
cases:14.29%
controls:7.09%
13
67
164
1698
15
30
162
1735
6
5
171
1760
—
—
14
47
156
1680
22
112
132
1468
Cardiology
6 [38004451]
6 [38004451]
1.1e+00
1.3e+00
—
—
—
1.8e+00
1.1e+00
cases:14.69%
controls:5.38%
cases:7.34%
controls:2.15%
—
—
—
—
—
—
cases:12.94%
controls:2.37%
cases:20.13%
controls:7.85%
26
95
151
1670
13
38
164
1727
—
—
—
22
41
148
1686
31
124
123
1456
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
6.9e-01
1.1e+00
—
—
2.7e+00
1.3e+00
5.7e-01
cases:9.60%
controls:5.04%
cases:8.47%
controls:2.89%
—
—
—
—
cases:5.08%
controls:0.34%
cases:8.24%
controls:2.43%
cases:13.64%
controls:8.16%
17
89
160
1676
15
51
162
1714
—
—
9
6
168
1756
14
42
156
1685
21
129
133
1451
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
5.3e-01
1.4e+00
2.3e+00
—
2.1e+00
1.2e+00
7.4e-01
cases:10.17%
controls:6.23%
cases:10.17%
controls:2.61%
cases:3.95%
controls:0.40%
—
—
cases:2.82%
controls:0.34%
cases:9.41%
controls:3.18%
cases:18.83%
controls:10.00%
18
110
159
1655
18
46
159
1719
7
7
170
1758
—
5
6
172
1756
16
55
154
1672
29
158
125
1422
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
2.4e-01
3.4e-01
8.3e-01
3.4e+00
6.5e-01
2.5e-01
1.8e-01
cases:48.02%
controls:42.15%
cases:45.20%
controls:36.88%
cases:28.25%
controls:14.67%
cases:17.51%
controls:0.68%
cases:24.86%
controls:14.76%
cases:45.29%
controls:39.09%
cases:61.69%
controls:57.41%
85
744
92
1021
80
651
97
1114
50
259
127
1506
31
12
146
1753
44
260
133
1502
77
675
93
1052
95
907
59
673
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
1.3e+00
2.5e+00
—
—
—
1.1e+00
1.1e+00
cases:9.60%
controls:2.83%
cases:4.52%
controls:0.40%
—
—
—
—
—
—
cases:2.94%
controls:1.04%
cases:9.74%
controls:3.42%
17
50
160
1715
8
7
169
1758
—
—
—
5
18
165
1709
15
54
139
1526
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
1.3e+00
2.3e+00
—
—
—
1.4e+00
1.3e+00
cases:11.86%
controls:3.63%
cases:6.78%
controls:0.74%
—
—
—
—
—
—
cases:4.71%
controls:1.22%
cases:13.64%
controls:4.11%
21
64
156
1701
12
13
165
1752
—
—
—
8
21
162
1706
21
65
133
1515
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
5.0e-01
9.1e-01
2.0e+00
—
1.6e+00
1.1e+00
6.4e-01
cases:7.34%
controls:4.59%
cases:7.91%
controls:3.34%
cases:5.65%
controls:0.79%
—
—
cases:4.52%
controls:0.91%
cases:11.18%
controls:3.94%
cases:12.99%
controls:7.28%
13
81
164
1684
14
59
163
1706
10
14
167
1751
—
8
16
169
1746
19
68
151
1659
20
115
134
1465
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
1.4e+00
1.8e+00
—
—
—
1.7e+00
1.5e+00
cases:7.91%
controls:2.04%
cases:5.08%
controls:0.85%
—
—
—
—
—
—
cases:4.12%
controls:0.75%
cases:10.39%
controls:2.59%
14
36
163
1729
9
15
168
1750
—
—
—
7
13
163
1714
16
41
138
1539
Check up of cardiac pacemaker
XFP20 [2001303367]
XFP20 [2001303367]
—
—
—
—
—
2.1e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.46%
cases:5.84%
controls:0.51%
—
—
—
—
—
6
8
164
1719
9
8
145
1572
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
9.6e-01
1.7e+00
—
—
—
1.8e+00
1.1e+00
cases:6.78%
controls:2.72%
cases:6.21%
controls:1.25%
—
—
—
—
—
—
cases:5.29%
controls:0.93%
cases:10.39%
controls:3.73%
12
48
165
1717
11
22
166
1743
—
—
—
9
16
161
1711
16
59
138
1521
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
9.9e-01
1.1e+00
1.2e+00
—
1.4e+00
1.3e+00
1.2e+00
cases:12.99%
controls:5.27%
cases:9.04%
controls:3.29%
cases:3.39%
controls:1.08%
—
—
cases:3.95%
controls:0.96%
cases:10.59%
controls:3.13%
cases:18.83%
controls:6.77%
23
93
154
1672
16
58
161
1707
6
19
171
1746
—
7
17
170
1745
18
54
152
1673
29
107
125
1473
temazepam; oral
N05CD07 [21604642]
N05CD07 [21604642]
1.4e+00
—
—
—
—
1.5e+00
1.6e+00
cases:6.78%
controls:1.81%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.33%
cases:11.04%
controls:2.53%
12
32
165
1733
—
—
—
—
10
23
160
1704
17
40
137
1540
Anxiety disorder, unspecified
F41.9 [45542849]
F41.9 [45542849]
2.0e+00
—
—
—
—
—
2.4e+00
cases:3.95%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.51%
7
10
170
1755
—
—
—
—
—
8
8
146
1572
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
8.7e-01
2.3e+00
—
—
—
2.0e+00
8.0e-01
cases:7.34%
controls:3.23%
cases:5.65%
controls:0.57%
—
—
—
—
—
—
cases:6.47%
controls:0.93%
cases:9.74%
controls:4.62%
13
57
164
1708
10
10
167
1755
—
—
—
11
16
159
1711
15
73
139
1507
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.7e+00
1.2e+00
1.9e+00
1.0e+50
1.4e+00
1.2e+00
1.4e+00
cases:22.03%
controls:4.93%
cases:8.47%
controls:2.61%
cases:3.39%
controls:0.51%
cases:2.82%
controls:0.00%
cases:2.82%
controls:0.68%
cases:6.47%
controls:1.97%
cases:19.48%
controls:5.57%
39
87
138
1678
15
46
162
1719
6
9
171
1756
5
0
172
1765
5
12
172
1750
11
34
159
1693
30
88
124
1492
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
5.1e-01
9.8e-01
7.0e-01
—
1.7e+00
8.8e-01
7.0e-01
cases:30.51%
controls:20.91%
cases:22.60%
controls:9.92%
cases:2.82%
controls:1.42%
—
—
cases:9.04%
controls:1.70%
cases:24.71%
controls:11.99%
cases:45.45%
controls:29.18%
54
369
123
1396
40
175
137
1590
5
25
172
1740
—
16
30
161
1732
42
207
128
1520
70
461
84
1119
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
8.4e-01
1.4e+00
2.0e+00
—
1.7e+00
7.6e-01
7.1e-01
cases:15.82%
controls:7.54%
cases:11.30%
controls:3.00%
cases:3.95%
controls:0.57%
—
—
cases:3.95%
controls:0.74%
cases:7.06%
controls:3.42%
cases:16.88%
controls:9.05%
28
133
149
1632
20
53
157
1712
7
10
170
1755
—
7
13
170
1749
12
59
158
1668
26
143
128
1437
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
8.4e-01
1.4e+00
2.0e+00
—
1.7e+00
7.6e-01
7.1e-01
cases:15.82%
controls:7.54%
cases:11.30%
controls:3.00%
cases:3.95%
controls:0.57%
—
—
cases:3.95%
controls:0.74%
cases:7.06%
controls:3.42%
cases:16.88%
controls:9.11%
28
133
149
1632
20
53
157
1712
7
10
170
1755
—
7
13
170
1749
12
59
158
1668
26
144
128
1436
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
6.6e-01
1.1e+00
2.7e+00
—
—
1.4e+00
6.3e-01
cases:7.91%
controls:4.25%
cases:6.78%
controls:2.32%
cases:3.95%
controls:0.28%
—
—
—
—
cases:7.65%
controls:1.97%
cases:12.34%
controls:6.96%
14
75
163
1690
12
41
165
1724
7
5
170
1760
—
—
13
34
157
1693
19
110
135
1470
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.1e+00
2.0e+00
—
—
—
2.0e+00
9.7e-01
cases:3.95%
controls:1.42%
cases:3.39%
controls:0.45%
—
—
—
—
—
—
cases:4.71%
controls:0.64%
cases:5.19%
controls:2.03%
7
25
170
1740
6
8
171
1757
—
—
—
8
11
162
1716
8
32
146
1548
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.9e-01
4.5e-01
2.1e+00
—
1.9e+00
5.6e-01
2.9e-01
cases:19.21%
controls:16.49%
cases:18.64%
controls:12.80%
cases:15.25%
controls:2.10%
—
—
cases:12.99%
controls:2.10%
cases:22.94%
controls:14.59%
cases:34.42%
controls:28.23%
34
291
143
1474
33
226
144
1539
27
37
150
1728
—
23
37
154
1725
39
252
131
1475
53
446
101
1134
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.8e-01
4.8e-01
2.1e+00
—
1.9e+00
5.7e-01
2.9e-01
cases:19.21%
controls:16.54%
cases:18.64%
controls:12.46%
cases:15.25%
controls:2.10%
—
—
cases:12.99%
controls:2.16%
cases:22.94%
controls:14.42%
cases:34.42%
controls:28.16%
34
292
143
1473
33
220
144
1545
27
37
150
1728
—
23
38
154
1724
39
249
131
1478
53
445
101
1135
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
5.2e-01
1.4e+00
1.6e+00
—
1.9e+00
8.6e-01
7.3e-01
cases:13.56%
controls:8.56%
cases:14.12%
controls:4.08%
cases:3.39%
controls:0.74%
—
—
cases:3.95%
controls:0.62%
cases:11.18%
controls:5.04%
cases:22.73%
controls:12.41%
24
151
153
1614
25
72
152
1693
6
13
171
1752
—
7
11
170
1751
19
87
151
1640
35
196
119
1384
General Surgery
2 [38004447]
2 [38004447]
6.8e-01
1.3e+00
1.1e+00
—
—
1.2e+00
7.4e-01
cases:31.07%
controls:18.64%
cases:15.82%
controls:4.82%
cases:3.39%
controls:1.19%
—
—
—
—
cases:15.29%
controls:5.15%
cases:29.22%
controls:16.52%
55
329
122
1436
28
85
149
1680
6
21
171
1744
—
—
26
89
144
1638
45
261
109
1319
Malaise and fatigue
R53 [45553741]
R53 [45553741]
1.6e+00
2.2e+00
—
—
—
1.4e+00
2.3e-01
cases:5.08%
controls:1.02%
cases:5.08%
controls:0.57%
—
—
—
—
—
—
cases:3.53%
controls:0.87%
cases:3.25%
controls:2.59%
9
18
168
1747
9
10
168
1755
—
—
—
6
15
164
1712
5
41
149
1539
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
—
1.4e+00
—
—
—
1.3e+00
1.1e+00
—
—
cases:6.21%
controls:1.59%
—
—
—
—
—
—
cases:6.47%
controls:1.85%
cases:9.09%
controls:3.23%
—
11
28
166
1737
—
—
—
11
32
159
1695
14
51
140
1529
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
7.9e-01
1.9e+00
—
—
—
1.6e+00
1.9e+00
cases:2.82%
controls:1.30%
cases:4.52%
controls:0.74%
—
—
—
—
—
—
cases:2.94%
controls:0.64%
cases:10.39%
controls:1.71%
5
23
172
1742
8
13
169
1752
—
—
—
5
11
165
1716
16
27
138
1553
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
1.1e+00
1.7e+00
—
—
—
2.0e+00
1.0e+00
cases:5.65%
controls:1.87%
cases:5.08%
controls:0.96%
—
—
—
—
—
—
cases:4.71%
controls:0.64%
cases:6.49%
controls:2.41%
10
33
167
1732
9
17
168
1748
—
—
—
8
11
162
1716
10
38
144
1542
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
5.3e-01
1.4e+00
—
—
—
1.4e+00
8.8e-01
cases:7.34%
controls:4.48%
cases:7.34%
controls:1.87%
—
—
—
—
—
—
cases:8.24%
controls:2.20%
cases:15.58%
controls:7.09%
13
79
164
1686
13
33
164
1732
—
—
—
14
38
156
1689
24
112
130
1468
Other specified special examinations
Z01.8 [45581003]
Z01.8 [45581003]
1.5e+00
—
—
—
—
2.2e+00
7.0e-01
cases:5.08%
controls:1.19%
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.41%
cases:5.84%
controls:2.97%
9
21
168
1744
—
—
—
—
6
7
164
1720
9
47
145
1533
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
4.6e-01
8.4e-01
9.4e-01
1.0e+00
9.8e-01
9.1e-01
7.6e-01
cases:87.57%
controls:81.70%
cases:86.44%
controls:73.31%
cases:61.02%
controls:37.90%
cases:5.65%
controls:2.15%
cases:61.02%
controls:36.95%
cases:87.65%
controls:74.00%
cases:95.45%
controls:90.76%
155
1442
22
323
153
1294
24
471
108
669
69
1096
10
38
167
1727
108
651
69
1111
149
1278
21
449
147
1434
7
146
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
1.3e+00
1.3e+00
—
—
—
2.4e+00
1.1e+00
cases:9.60%
controls:2.83%
cases:3.39%
controls:0.91%
—
—
—
—
—
—
cases:5.88%
controls:0.58%
cases:7.79%
controls:2.85%
17
50
160
1715
6
16
171
1749
—
—
—
10
10
160
1717
12
45
142
1535
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
5.3e-01
1.1e+00
—
—
2.5e+00
7.7e-01
5.9e-01
cases:22.60%
controls:14.62%
cases:12.99%
controls:4.59%
—
—
—
—
cases:3.39%
controls:0.28%
cases:10.59%
controls:5.21%
cases:25.32%
controls:15.82%
40
258
137
1507
23
81
154
1684
—
—
6
5
171
1757
18
90
152
1637
39
250
115
1330
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
1.1e+00
2.1e+00
—
—
—
1.6e+00
6.9e-01
cases:5.65%
controls:2.04%
cases:5.08%
controls:0.68%
—
—
—
—
—
—
cases:5.88%
controls:1.27%
cases:8.44%
controls:4.43%
10
36
167
1729
9
12
168
1753
—
—
—
10
22
160
1705
13
70
141
1510
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
4.2e-01
7.2e-01
2.2e+00
—
1.4e+00
6.1e-01
3.4e-01
cases:16.95%
controls:11.78%
cases:16.95%
controls:9.07%
cases:12.99%
controls:1.64%
—
—
cases:7.91%
controls:1.99%
cases:18.24%
controls:10.83%
cases:25.97%
controls:20.06%
30
208
147
1557
30
160
147
1605
23
29
154
1736
—
14
35
163
1727
31
187
139
1540
40
317
114
1263
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
8.7e-01
1.0e+00
—
—
—
2.2e+00
1.4e+00
cases:5.65%
controls:2.44%
cases:3.95%
controls:1.47%
—
—
—
—
—
—
cases:7.06%
controls:0.81%
cases:12.99%
controls:3.54%
10
43
167
1722
7
26
170
1739
—
—
—
12
14
158
1713
20
56
134
1524
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
1.5e+00
—
—
—
—
2.0e+00
1.6e+00
cases:3.39%
controls:0.79%
—
—
—
—
—
—
—
—
cases:5.29%
controls:0.75%
cases:7.79%
controls:1.71%
6
14
171
1751
—
—
—
—
9
13
161
1714
12
27
142
1553
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.5e-01
5.2e-01
2.0e+00
—
1.6e+00
4.7e-01
1.6e-01
cases:20.34%
controls:18.07%
cases:22.03%
controls:14.39%
cases:15.82%
controls:2.49%
—
—
cases:12.43%
controls:2.89%
cases:24.12%
controls:16.56%
cases:33.77%
controls:30.32%
36
319
141
1446
39
254
138
1511
28
44
149
1721
—
22
51
155
1711
41
286
129
1441
52
479
102
1101
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
1.2e+00
1.9e+00
—
—
—
1.7e+00
1.1e+00
cases:6.78%
controls:2.10%
cases:3.95%
controls:0.62%
—
—
—
—
—
—
cases:4.71%
controls:0.93%
cases:7.79%
controls:2.78%
12
37
165
1728
7
11
170
1754
—
—
—
8
16
162
1711
12
44
142
1536
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
6.8e-02
4.1e-01
2.1e+00
—
1.4e+00
3.7e-01
1.7e-01
cases:21.47%
controls:20.34%
cases:23.73%
controls:17.05%
cases:18.08%
controls:2.66%
—
—
cases:12.99%
controls:3.41%
cases:24.12%
controls:18.01%
cases:36.36%
controls:32.53%
38
359
139
1406
42
301
135
1464
32
47
145
1718
—
23
60
154
1702
41
311
129
1416
56
514
98
1066
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
1.0e+00
2.0e+00
—
—
—
—
1.5e+00
cases:3.95%
controls:1.47%
cases:3.39%
controls:0.45%
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.71%
7
26
170
1739
6
8
171
1757
—
—
—
—
11
27
143
1553
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
6.1e-02
4.1e-01
2.1e+00
—
1.4e+00
3.7e-01
1.4e-01
cases:21.47%
controls:20.45%
cases:23.73%
controls:17.11%
cases:18.08%
controls:2.66%
—
—
cases:12.99%
controls:3.46%
cases:24.12%
controls:18.01%
cases:35.71%
controls:32.59%
38
361
139
1404
42
302
135
1463
32
47
145
1718
—
23
61
154
1701
41
311
129
1416
55
515
99
1065
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
6.8e-02
4.1e-01
2.0e+00
—
1.5e+00
3.7e-01
1.5e-01
cases:21.47%
controls:20.34%
cases:23.73%
controls:17.11%
cases:17.51%
controls:2.66%
—
—
cases:12.99%
controls:3.35%
cases:24.12%
controls:18.01%
cases:35.71%
controls:32.34%
38
359
139
1406
42
302
135
1463
31
47
146
1718
—
23
59
154
1703
41
311
129
1416
55
511
99
1069
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
1.1e-01
3.1e-01
2.1e+00
1.0e+50
1.4e+00
3.2e-01
2.6e-01
cases:18.08%
controls:16.49%
cases:14.69%
controls:11.22%
cases:9.60%
controls:1.30%
cases:2.82%
controls:0.00%
cases:7.91%
controls:2.04%
cases:15.88%
controls:12.10%
cases:29.87%
controls:24.68%
32
291
145
1474
26
198
151
1567
17
23
160
1742
5
0
172
1765
14
36
163
1726
27
209
143
1518
46
390
108
1190
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
6.5e-02
4.1e-01
2.0e+00
—
1.4e+00
3.7e-01
1.4e-01
cases:21.47%
controls:20.40%
cases:23.73%
controls:17.11%
cases:17.51%
controls:2.66%
—
—
cases:12.99%
controls:3.41%
cases:24.12%
controls:18.01%
cases:35.71%
controls:32.47%
38
360
139
1405
42
302
135
1463
31
47
146
1718
—
23
60
154
1702
41
311
129
1416
55
513
99
1067
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
6.5e-02
4.1e-01
2.0e+00
—
1.4e+00
3.7e-01
1.5e-01
cases:21.47%
controls:20.40%
cases:23.73%
controls:17.11%
cases:17.51%
controls:2.66%
—
—
cases:12.99%
controls:3.41%
cases:24.12%
controls:17.95%
cases:35.71%
controls:32.41%
38
360
139
1405
42
302
135
1463
31
47
146
1718
—
23
60
154
1702
41
310
129
1417
55
512
99
1068
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
6.5e-02
4.1e-01
2.0e+00
—
1.4e+00
3.7e-01
1.4e-01
cases:21.47%
controls:20.40%
cases:23.73%
controls:17.11%
cases:17.51%
controls:2.66%
—
—
cases:12.99%
controls:3.41%
cases:24.12%
controls:18.01%
cases:35.71%
controls:32.47%
38
360
139
1405
42
302
135
1463
31
47
146
1718
—
23
60
154
1702
41
311
129
1416
55
513
99
1067
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
6.8e-02
4.1e-01
2.0e+00
—
1.4e+00
3.7e-01
1.5e-01
cases:21.47%
controls:20.34%
cases:23.73%
controls:17.05%
cases:17.51%
controls:2.66%
—
—
cases:12.99%
controls:3.41%
cases:24.12%
controls:17.95%
cases:35.71%
controls:32.41%
38
359
139
1406
42
301
135
1464
31
47
146
1718
—
23
60
154
1702
41
310
129
1417
55
512
99
1068
zolpidem; oral
N05CF02 [21604655]
N05CF02 [21604655]
1.1e+00
2.1e+00
—
—
—
1.5e+00
1.3e+00
cases:5.65%
controls:1.87%
cases:5.08%
controls:0.62%
—
—
—
—
—
—
cases:2.94%
controls:0.69%
cases:8.44%
controls:2.34%
10
33
167
1732
9
11
168
1754
—
—
—
5
12
165
1715
13
37
141
1543
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
1.8e-02
4.3e-01
2.1e+00
—
1.3e+00
3.3e-01
1.8e-01
cases:15.82%
controls:15.58%
cases:17.51%
controls:12.12%
cases:13.56%
controls:1.81%
—
—
cases:7.91%
controls:2.21%
cases:16.47%
controls:12.39%
cases:27.92%
controls:24.37%
28
275
149
1490
31
214
146
1551
24
32
153
1733
—
14
39
163
1723
28
214
142
1513
43
385
111
1195
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
N05BA01 [21604566]
8.8e-01
1.0e+00
—
—
—
1.7e+00
1.6e+00
cases:4.52%
controls:1.93%
cases:2.82%
controls:1.02%
—
—
—
—
—
—
cases:5.29%
controls:0.98%
cases:9.09%
controls:1.96%
8
34
169
1731
5
18
172
1747
—
—
—
9
17
161
1710
14
31
140
1549
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
6.1e-02
3.2e-01
1.9e+00
—
1.3e+00
5.5e-01
3.6e-01
cases:13.56%
controls:12.86%
cases:14.12%
controls:10.65%
cases:11.30%
controls:1.81%
—
—
cases:7.91%
controls:2.21%
cases:18.24%
controls:11.41%
cases:27.27%
controls:20.70%
24
227
153
1538
25
188
152
1577
20
32
157
1733
—
14
39
163
1723
31
197
139
1530
42
327
112
1253
ezetimibe; oral
C10AX09 [21601896]
C10AX09 [21601896]
1.7e+00
1.9e+00
—
—
—
1.3e+00
1.4e+00
cases:3.95%
controls:0.74%
cases:4.52%
controls:0.74%
—
—
—
—
—
—
cases:3.53%
controls:0.98%
cases:6.49%
controls:1.71%
7
13
170
1752
8
13
169
1752
—
—
—
6
17
164
1710
10
27
144
1553
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
1.8e+00
—
—
—
—
—
1.4e+00
cases:6.78%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:1.71%
12
20
165
1745
—
—
—
—
—
10
27
144
1553
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
1.3e+00
—
—
—
—
1.9e+00
1.3e+00
cases:3.39%
controls:0.91%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.75%
cases:7.79%
controls:2.15%
6
16
171
1749
—
—
—
—
8
13
162
1714
12
34
142
1546
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
4.1e-01
1.6e+00
—
—
—
1.5e+00
9.7e-01
cases:3.39%
controls:2.27%
cases:5.08%
controls:1.02%
—
—
—
—
—
—
cases:6.47%
controls:1.45%
cases:9.74%
controls:3.92%
6
40
171
1725
9
18
168
1747
—
—
—
11
25
159
1702
15
62
139
1518
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
1.2e+00
—
—
—
—
1.7e+00
1.5e+00
cases:3.39%
controls:1.02%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.87%
cases:9.09%
controls:2.28%
6
18
171
1747
—
—
—
—
8
15
162
1712
14
36
140
1544
Chest pain, unspecified
R07.4 [45558450]
R07.4 [45558450]
1.1e+00
—
—
—
—
2.0e+00
9.4e-01
cases:8.47%
controls:3.06%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.64%
cases:8.44%
controls:3.48%
15
54
162
1711
—
—
—
—
8
11
162
1716
13
55
141
1525
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
—
1.5e+00
—
—
—
1.8e+00
1.3e+00
—
—
cases:2.82%
controls:0.62%
—
—
—
—
—
—
cases:4.12%
controls:0.69%
cases:7.79%
controls:2.28%
—
5
11
172
1754
—
—
—
7
12
163
1715
12
36
142
1544
Otolaryngology
4 [38004449]
4 [38004449]
7.0e-01
9.1e-01
—
—
2.3e+00
9.1e-01
7.6e-01
cases:17.51%
controls:9.58%
cases:7.91%
controls:3.34%
—
—
—
—
cases:3.39%
controls:0.34%
cases:8.24%
controls:3.47%
cases:19.48%
controls:10.13%
31
169
146
1596
14
59
163
1706
—
—
6
6
171
1756
14
60
156
1667
30
160
124
1420
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
9.7e-01
1.5e+00
—
1.0e+50
—
1.7e+00
1.3e+00
cases:4.52%
controls:1.76%
cases:4.52%
controls:1.08%
—
—
cases:2.82%
controls:0.00%
—
—
cases:5.29%
controls:0.98%
cases:9.74%
controls:2.72%
8
31
169
1734
8
19
169
1746
—
5
0
172
1765
—
9
17
161
1710
15
43
139
1537
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
6.6e-01
1.7e+00
—
—
—
1.4e+00
7.4e-01
cases:4.52%
controls:2.38%
cases:5.65%
controls:1.13%
—
—
—
—
—
—
cases:5.88%
controls:1.51%
cases:9.74%
controls:4.87%
8
42
169
1723
10
20
167
1745
—
—
—
10
26
160
1701
15
77
139
1503
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
14920-3 [3008486]
4.5e-01
9.7e-01
2.0e+00
—
—
6.3e-01
3.5e-01
cases:14.12%
controls:9.52%
cases:11.86%
controls:4.87%
cases:3.39%
controls:0.45%
—
—
—
—
cases:10.59%
controls:5.91%
cases:22.73%
controls:17.22%
25
168
152
1597
21
86
156
1679
6
8
171
1757
—
—
18
102
152
1625
35
272
119
1308
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
1.2e+00
1.7e+00
—
—
—
8.3e-01
5.6e-01
cases:6.78%
controls:2.04%
cases:6.78%
controls:1.25%
—
—
—
—
—
—
cases:3.53%
controls:1.56%
cases:7.79%
controls:4.62%
12
36
165
1729
12
22
165
1743
—
—
—
6
27
164
1700
12
73
142
1507
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
1.0e+00
8.8e-01
—
—
1.0e+00
1.0e+00
9.5e-01
cases:15.82%
controls:6.35%
cases:11.30%
controls:5.04%
—
—
—
—
cases:3.39%
controls:1.25%
cases:14.12%
controls:5.62%
cases:17.53%
controls:7.59%
28
112
149
1653
20
89
157
1676
—
—
6
22
171
1740
24
97
146
1630
27
120
127
1460
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.4e+00
—
—
—
—
—
1.5e+00
cases:5.65%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:1.77%
10
25
167
1740
—
—
—
—
—
12
28
142
1552
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
7.8e-01
1.2e+00
—
—
—
1.9e+00
1.1e+00
cases:8.47%
controls:4.08%
cases:6.78%
controls:2.21%
—
—
—
—
—
—
cases:7.65%
controls:1.22%
cases:13.64%
controls:5.19%
15
72
162
1693
12
39
165
1726
—
—
—
13
21
157
1706
21
82
133
1498
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
1.3e+00
1.6e+00
—
—
—
1.1e+00
9.1e-01
cases:13.56%
controls:4.08%
cases:5.08%
controls:1.02%
—
—
—
—
—
—
cases:2.94%
controls:1.04%
cases:11.69%
controls:5.06%
24
72
153
1693
9
18
168
1747
—
—
—
5
18
165
1709
18
80
136
1500
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
1.2e+00
1.7e+00
—
—
—
1.8e+00
1.1e+00
cases:5.08%
controls:1.64%
cases:3.39%
controls:0.62%
—
—
—
—
—
—
cases:4.12%
controls:0.69%
cases:8.44%
controls:2.91%
9
29
168
1736
6
11
171
1754
—
—
—
7
12
163
1715
13
46
141
1534
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
1.5e+00
1.4e+00
-1.0e+50
—
—
1.3e+00
1.4e+00
cases:11.30%
controls:2.89%
cases:5.08%
controls:1.25%
cases:0.00%
controls:0.28%
—
—
—
—
cases:4.71%
controls:1.33%
cases:11.04%
controls:2.85%
20
51
157
1714
9
22
168
1743
0
5
177
1760
—
—
8
23
162
1704
17
45
137
1535
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
—
1.4e+00
—
—
—
1.5e+00
8.8e-01
—
—
cases:8.47%
controls:2.15%
—
—
—
—
—
—
cases:8.82%
controls:2.20%
cases:12.34%
controls:5.51%
—
15
38
162
1727
—
—
—
15
38
155
1689
19
87
135
1493
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
2.9e-01
9.6e-01
1.9e+00
—
1.1e+00
3.0e-01
4.1e-01
cases:16.38%
controls:12.75%
cases:16.38%
controls:6.97%
cases:5.08%
controls:0.79%
—
—
cases:2.82%
controls:0.96%
cases:11.76%
controls:8.98%
cases:29.22%
controls:21.58%
29
225
148
1540
29
123
148
1642
9
14
168
1751
—
5
17
172
1745
20
155
150
1572
45
341
109
1239
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.32%
—
—
—
—
—
—
8
5
146
1575
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
38445-3 [3048689]
1.4e+00
2.8e+00
—
—
—
—
—
cases:3.95%
controls:1.02%
cases:8.47%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
7
18
170
1747
15
10
162
1755
—
—
—
—
—
Syncope and collapse
R55 [45568141]
R55 [45568141]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.44%
controls:0.57%
—
—
—
—
—
—
13
9
141
1571
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
-1.7e-01
1.4e+00
—
—
—
1.3e+00
9.0e-01
cases:2.82%
controls:3.34%
cases:6.78%
controls:1.76%
—
—
—
—
—
—
cases:7.65%
controls:2.14%
cases:11.69%
controls:5.13%
5
59
172
1706
12
31
165
1734
—
—
—
13
37
157
1690
18
81
136
1499
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
4.4e-01
5.1e-01
2.1e+00
—
1.3e+00
3.7e-01
6.4e-01
cases:20.90%
controls:14.50%
cases:11.30%
controls:7.08%
cases:6.78%
controls:0.91%
—
—
cases:2.82%
controls:0.79%
cases:8.24%
controls:5.85%
cases:28.57%
controls:17.41%
37
256
140
1509
20
125
157
1640
12
16
165
1749
—
5
14
172
1748
14
101
156
1626
44
275
110
1305
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
1.1e+00
—
—
—
—
2.6e+00
1.0e+00
cases:5.65%
controls:2.04%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.35%
cases:5.84%
controls:2.15%
10
36
167
1729
—
—
—
—
8
6
162
1721
9
34
145
1546
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
8.1e-01
1.8e+00
—
—
—
1.2e+00
8.8e-01
cases:9.04%
controls:4.25%
cases:6.21%
controls:1.13%
—
—
—
—
—
—
cases:5.88%
controls:1.85%
cases:14.29%
controls:6.46%
16
75
161
1690
11
20
166
1745
—
—
—
10
32
160
1695
22
102
132
1478
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
6.4e-01
1.2e+00
1.2e+00
—
—
1.4e+00
8.0e-01
cases:4.52%
controls:2.44%
cases:6.78%
controls:2.04%
cases:2.82%
controls:0.85%
—
—
—
—
cases:8.24%
controls:2.20%
cases:11.69%
controls:5.63%
8
43
169
1722
12
36
165
1729
5
15
172
1750
—
—
14
38
156
1689
18
89
136
1491
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
Z03 [45552058]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:0.44%
—
—
—
—
—
—
9
7
145
1573
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
1.2e+00
2.6e+00
—
—
—
—
—
cases:3.39%
controls:1.02%
cases:4.52%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
6
18
171
1747
8
6
169
1759
—
—
—
—
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
6.8e-01
1.6e+00
—
—
—
9.5e-01
1.0e+00
cases:9.60%
controls:5.10%
cases:7.91%
controls:1.70%
—
—
—
—
—
—
cases:3.53%
controls:1.39%
cases:14.94%
controls:5.95%
17
90
160
1675
14
30
163
1735
—
—
—
6
24
164
1703
23
94
131
1486
Foot/toe symptom/complaint
L17 [2002000641]
L17 [2002000641]
6.4e-01
—
—
—
—
1.5e+00
1.1e+00
cases:4.52%
controls:2.44%
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.22%
cases:10.39%
controls:3.80%
8
43
169
1722
—
—
—
—
9
21
161
1706
16
60
138
1520
bisoprolol; oral
C07AB07 [21601689]
C07AB07 [21601689]
6.8e-01
7.9e-01
3.5e-01
—
8.5e-01
7.5e-01
1.0e+00
cases:18.64%
controls:10.37%
cases:16.95%
controls:8.50%
cases:3.95%
controls:2.83%
—
—
cases:6.78%
controls:3.01%
cases:18.24%
controls:9.50%
cases:29.87%
controls:13.29%
33
183
144
1582
30
150
147
1615
7
50
170
1715
—
12
53
165
1709
31
164
139
1563
46
210
108
1370
Infectious Disease
44 [38004484]
44 [38004484]
1.8e+00
—
—
1.0e+50
—
—
2.6e+00
cases:3.39%
controls:0.57%
—
—
—
—
cases:18.64%
controls:0.00%
—
—
—
—
cases:9.74%
controls:0.82%
6
10
171
1755
—
—
33
0
144
1765
—
—
15
13
139
1567
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
—
2.5e+00
—
—
—
—
8.1e-01
—
—
cases:3.39%
controls:0.28%
—
—
—
—
—
—
—
—
cases:3.90%
controls:1.77%
—
6
5
171
1760
—
—
—
—
6
28
148
1552
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
—
2.5e+00
—
—
—
—
7.0e-01
—
—
cases:3.39%
controls:0.28%
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.65%
—
6
5
171
1760
—
—
—
—
5
26
149
1554
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
C44.31 [2000500792]
—
2.5e+00
—
—
—
—
—
—
—
cases:3.39%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
6
5
171
1760
—
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
AA1BG [2001300112]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.44%
—
—
—
—
—
—
8
7
146
1573
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
R41.8 [45534452]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.44%
—
—
—
—
—
—
8
7
146
1573
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
1.2e+00
1.4e+00
—
—
—
—
1.2e+00
cases:6.78%
controls:2.04%
cases:2.82%
controls:0.68%
—
—
—
—
—
—
—
—
cases:8.44%
controls:2.59%
12
36
165
1729
5
12
172
1753
—
—
—
—
13
41
141
1539
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
—
2.5e+00
—
—
—
—
8.7e-01
—
—
cases:3.95%
controls:0.34%
—
—
—
—
—
—
—
—
cases:4.55%
controls:1.96%
—
7
6
170
1759
—
—
—
—
7
31
147
1549
Hematology
82 [38004501]
82 [38004501]
—
2.5e+00
—
1.0e+50
—
—
1.4e+00
—
—
cases:5.65%
controls:0.51%
—
—
cases:2.82%
controls:0.00%
—
—
—
—
cases:5.19%
controls:1.33%
—
10
9
167
1756
—
5
0
172
1765
—
—
8
21
146
1559
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
6.5e-01
1.1e+00
1.4e+00
—
1.2e+00
1.2e+00
7.2e-01
cases:9.04%
controls:4.93%
cases:8.47%
controls:2.89%
cases:5.08%
controls:1.25%
—
—
cases:2.82%
controls:0.85%
cases:9.41%
controls:2.90%
cases:14.29%
controls:7.53%
16
87
161
1678
15
51
162
1714
9
22
168
1743
—
5
15
172
1747
16
50
154
1677
22
119
132
1461
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
9.7e-01
1.8e+00
—
—
—
2.4e+00
1.2e+00
cases:5.65%
controls:2.21%
cases:3.39%
controls:0.57%
—
—
—
—
—
—
cases:4.71%
controls:0.46%
cases:7.79%
controls:2.47%
10
39
167
1726
6
10
171
1755
—
—
—
8
8
162
1719
12
39
142
1541
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
2.3e+00
1.8e+00
—
—
—
2.0e+00
1.2e+00
cases:5.65%
controls:0.57%
cases:3.39%
controls:0.57%
—
—
—
—
—
—
cases:2.94%
controls:0.41%
cases:6.49%
controls:2.03%
10
10
167
1755
6
10
171
1755
—
—
—
5
7
165
1720
10
32
144
1548
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.29%
—
—
—
—
—
—
—
5
5
165
1722
—
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
1.2e+00
—
—
—
—
—
2.3e+00
cases:2.82%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.82%
5
15
172
1750
—
—
—
—
—
12
13
142
1567
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
1.2e+00
—
—
—
—
—
2.3e+00
cases:2.82%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.82%
5
15
172
1750
—
—
—
—
—
12
13
142
1567
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
1.2e+00
—
—
—
—
—
2.3e+00
cases:2.82%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.82%
5
15
172
1750
—
—
—
—
—
12
13
142
1567
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
1.2e+00
—
—
—
—
—
2.3e+00
cases:2.82%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.82%
5
15
172
1750
—
—
—
—
—
12
13
142
1567
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
1.2e+00
—
—
—
—
—
2.3e+00
cases:2.82%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.82%
5
15
172
1750
—
—
—
—
—
12
13
142
1567
Concussion
S06.0 [45582805]
S06.0 [45582805]
1.7e+00
—
—
—
—
—
2.3e+00
cases:3.39%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.57%
6
11
171
1754
—
—
—
—
—
8
9
146
1571
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
8.8e-01
—
—
—
—
—
2.2e+00
cases:2.82%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.89%
5
21
172
1744
—
—
—
—
—
12
14
142
1566
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
8.8e-01
—
—
—
—
—
2.2e+00
cases:2.82%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.89%
5
21
172
1744
—
—
—
—
—
12
14
142
1566
FEV1
20150-9 [3024653]
20150-9 [3024653]
8.8e-01
—
—
—
—
—
2.2e+00
cases:2.82%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:0.89%
5
21
172
1744
—
—
—
—
—
12
14
142
1566
pivmecillinam; oral
J01CA08 [21602827]
J01CA08 [21602827]
1.2e+00
7.9e-01
—
—
—
1.2e-01
1.0e+00
cases:16.38%
controls:5.72%
cases:5.08%
controls:2.38%
—
—
—
—
—
—
cases:2.94%
controls:2.61%
cases:17.53%
controls:7.03%
29
101
148
1664
9
42
168
1723
—
—
—
5
45
165
1682
27
111
127
1469
epinephrine; parenteral
C01CA24 [21600303]
C01CA24 [21600303]
2.2e+00
—
—
—
—
—
1.4e+00
cases:3.95%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.82%
7
8
170
1757
—
—
—
—
—
5
13
149
1567
Atrial fibrillation and flutter
I48 [45596206]
I48 [45596206]
8.0e-01
9.0e-01
2.2e+00
1.0e+50
—
1.3e+00
6.2e-01
cases:6.78%
controls:3.17%
cases:3.95%
controls:1.64%
cases:3.95%
controls:0.45%
cases:2.82%
controls:0.00%
—
—
cases:6.47%
controls:1.91%
cases:7.79%
controls:4.37%
12
56
165
1709
7
29
170
1736
7
8
170
1757
5
0
172
1765
—
11
33
159
1694
12
69
142
1511
epinephrine
S01EA01 [21603673]
S01EA01 [21603673]
2.2e+00
—
—
—
—
—
1.4e+00
cases:3.95%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.82%
7
8
170
1757
—
—
—
—
—
5
13
149
1567
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
20740-7 [3006418]
2.2e+00
—
—
—
—
—
—
cases:3.39%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
171
1758
—
—
—
—
—
—
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
82300-5 [42529406]
2.2e+00
—
—
—
—
—
—
cases:3.39%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
171
1758
—
—
—
—
—
—
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
28549-4 [3014765]
2.2e+00
—
—
—
—
—
—
cases:3.39%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
171
1758
—
—
—
—
—
—
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
1.1e+00
1.6e+00
—
—
—
—
1.1e+00
cases:9.04%
controls:3.34%
cases:3.95%
controls:0.85%
—
—
—
—
—
—
—
—
cases:11.69%
controls:4.18%
16
59
161
1706
7
15
170
1750
—
—
—
—
18
66
136
1514
pramipexole; oral
N04BC05 [21604477]
N04BC05 [21604477]
1.7e+00
—
-1.0e+50
—
—
—
2.1e+00
cases:3.95%
controls:0.74%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:5.19%
controls:0.63%
7
13
170
1752
—
0
5
177
1760
—
—
—
8
10
146
1570
Acute tubulo-interstitial nephritis
N10 [45543856]
N10 [45543856]
2.1e+00
—
—
—
—
—
—
cases:5.08%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
9
11
168
1754
—
—
—
—
—
—
Headache
R51.80 [2000503603]
R51.80 [2000503603]
2.1e+00
—
—
—
—
—
1.3e+00
cases:6.78%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.58%
12
15
165
1750
—
—
—
—
—
9
25
145
1555
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
9.8e-01
2.1e+00
1.0e+50
—
—
1.2e+00
2.4e-01
cases:3.39%
controls:1.30%
cases:6.78%
controls:0.85%
cases:2.82%
controls:0.00%
—
—
—
—
cases:3.53%
controls:1.10%
cases:3.90%
controls:3.10%
6
23
171
1742
12
15
165
1750
5
0
172
1765
—
—
6
19
164
1708
6
49
148
1531
Emergency Medicine
93 [38004510]
93 [38004510]
4.9e-01
1.1e+00
1.8e+00
—
1.9e+00
1.0e+00
6.2e-01
cases:11.30%
controls:7.25%
cases:11.30%
controls:4.19%
cases:3.39%
controls:0.57%
—
—
cases:3.39%
controls:0.51%
cases:12.35%
controls:4.75%
cases:20.13%
controls:11.96%
20
128
157
1637
20
74
157
1691
6
10
171
1755
—
6
9
171
1753
21
82
149
1645
31
189
123
1391
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
F32.10 [2000501980]
2.1e+00
—
—
—
—
—
—
cases:3.95%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
170
1756
—
—
—
—
—
—
amitriptyline and psycholeptics
N06CA01 [21604789]
N06CA01 [21604789]
1.2e+00
1.9e+00
—
—
—
—
2.1e+00
cases:3.39%
controls:1.08%
cases:2.82%
controls:0.45%
—
—
—
—
—
—
—
—
cases:7.14%
controls:0.95%
6
19
171
1746
5
8
172
1757
—
—
—
—
11
15
143
1565
Pain general/multiple sites
A01 [2002000142]
A01 [2002000142]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.51%
—
—
—
—
—
—
6
8
148
1572
Constipation, unspecified
K59.09 [2000502926]
K59.09 [2000502926]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.51%
—
—
—
—
—
—
6
8
148
1572
Assessment of need for aid
SPAT1229 [2001700330]
SPAT1229 [2001700330]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:0.51%
—
—
—
—
—
—
6
8
148
1572
levocetirizine; oral
R06AE09 [21603498]
R06AE09 [21603498]
7.0e-01
—
—
—
—
2.1e+00
—
cases:2.82%
controls:1.42%
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.46%
—
—
5
25
172
1740
—
—
—
—
6
8
164
1719
—
Periodontal treatment by dental hygienist
SDE02 [2001310350]
SDE02 [2001310350]
4.9e-01
—
—
—
—
2.0e+00
5.3e-01
cases:3.39%
controls:2.10%
—
—
—
—
—
—
—
—
cases:4.71%
controls:0.64%
cases:4.55%
controls:2.72%
6
37
171
1728
—
—
—
—
8
11
162
1716
7
43
147
1537
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
20955-1 [3004716]
2.0e+00
—
—
—
—
—
1.3e+00
cases:4.52%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.89%
8
11
169
1754
—
—
—
—
—
5
14
149
1566
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
1.1e+00
—
—
—
—
—
2.0e+00
cases:3.39%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.01%
6
21
171
1744
—
—
—
—
—
11
16
143
1564
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
1.1e+00
—
—
—
—
—
2.0e+00
cases:3.39%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.01%
6
21
171
1744
—
—
—
—
—
11
16
143
1564
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
31017-7 [3019050]
1.0e+00
2.0e+00
—
—
—
—
4.2e-01
cases:4.52%
controls:1.64%
cases:6.78%
controls:0.96%
—
—
—
—
—
—
—
—
cases:5.19%
controls:3.48%
8
29
169
1736
12
17
165
1748
—
—
—
—
8
55
146
1525
Unspecified fall
W19 [45756257]
W19 [45756257]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.63%
—
—
—
—
—
—
7
10
147
1570
Nephrology
39 [38004479]
39 [38004479]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.63%
—
—
—
—
—
—
7
10
147
1570
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
2.0e-01
6.1e-01
2.0e+00
—
1.2e+00
4.1e-01
2.7e-01
cases:20.34%
controls:17.22%
cases:19.77%
controls:11.78%
cases:12.43%
controls:1.87%
—
—
cases:6.78%
controls:2.21%
cases:19.41%
controls:13.72%
cases:33.12%
controls:27.41%
36
304
141
1461
35
208
142
1557
22
33
155
1732
—
12
39
165
1723
33
237
137
1490
51
433
103
1147
loperamide oxide; oral
A07DA05 [21600648]
A07DA05 [21600648]
1.5e+00
—
—
—
—
2.0e+00
—
cases:3.39%
controls:0.79%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.58%
—
—
6
14
171
1751
—
—
—
—
7
10
163
1717
—
loperamide; oral
A07DA03 [21600646]
A07DA03 [21600646]
1.5e+00
—
—
—
—
2.0e+00
—
cases:3.39%
controls:0.79%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.58%
—
—
6
14
171
1751
—
—
—
—
7
10
163
1717
—
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
5.8e-01
2.0e+00
—
—
—
—
8.7e-01
cases:6.21%
controls:3.57%
cases:3.95%
controls:0.57%
—
—
—
—
—
—
—
—
cases:8.44%
controls:3.73%
11
63
166
1702
7
10
170
1755
—
—
—
—
13
59
141
1521
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.2e+00
-1.7e-01
—
—
—
—
3.1e+00
cases:10.73%
controls:27.93%
cases:6.21%
controls:7.31%
—
—
—
—
—
—
—
—
cases:16.88%
controls:0.89%
19
493
158
1272
11
129
166
1636
—
—
—
—
26
14
128
1566
quetiapine; oral
N05AH04 [21604544]
N05AH04 [21604544]
1.2e+00
1.4e+00
—
—
—
1.9e+00
1.1e+00
cases:5.65%
controls:1.70%
cases:4.52%
controls:1.19%
—
—
—
—
—
—
cases:6.47%
controls:0.98%
cases:7.14%
controls:2.47%
10
30
167
1735
8
21
169
1744
—
—
—
11
17
159
1710
11
39
143
1541
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
7.7e-01
—
—
—
—
—
1.9e+00
cases:3.95%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:1.20%
7
33
170
1732
—
—
—
—
—
12
19
142
1561
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
8.9e-01
1.9e+00
—
—
—
—
6.6e-01
cases:3.39%
controls:1.42%
cases:4.52%
controls:0.68%
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.71%
6
25
171
1740
8
12
169
1753
—
—
—
—
5
27
149
1553
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
5.1e-01
1.2e+00
—
—
8.8e-01
7.5e-01
7.4e-01
cases:33.90%
controls:23.51%
cases:18.08%
controls:6.35%
—
—
—
—
cases:2.82%
controls:1.19%
cases:12.94%
controls:6.54%
cases:40.91%
controls:24.75%
60
415
117
1350
32
112
145
1653
—
—
5
21
172
1741
22
113
148
1614
63
391
91
1189
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
10704-5 [3003327]
—
1.0e+50
—
—
—
—
1.9e+00
—
—
cases:8.47%
controls:0.00%
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.70%
—
15
0
162
1765
—
—
—
—
7
11
147
1569
salmeterol and fluticasone
R03AK06 [21603280]
R03AK06 [21603280]
1.1e+00
1.9e+00
—
—
—
1.5e+00
1.1e+00
cases:4.52%
controls:1.59%
cases:5.08%
controls:0.79%
—
—
—
—
—
—
cases:4.71%
controls:1.10%
cases:5.19%
controls:1.71%
8
28
169
1737
9
14
168
1751
—
—
—
8
19
162
1708
8
27
146
1553
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
9.2e-01
7.2e-01
—
—
1.3e+00
9.7e-01
9.7e-01
cases:12.99%
controls:5.61%
cases:6.21%
controls:3.12%
—
—
—
—
cases:2.82%
controls:0.79%
cases:8.82%
controls:3.53%
cases:16.23%
controls:6.84%
23
99
154
1666
11
55
166
1710
—
—
5
14
172
1748
15
61
155
1666
25
108
129
1472
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
A09 [45605189]
1.9e+00
—
—
1.0e+50
1.0e+50
—
1.1e+00
cases:5.65%
controls:0.91%
—
—
—
—
cases:6.21%
controls:0.00%
cases:4.52%
controls:0.00%
—
—
cases:4.55%
controls:1.52%
10
16
167
1749
—
—
11
0
166
1765
8
0
169
1762
—
7
24
147
1556
hydroxyzine; oral, parenteral
N05BB01 [21604590]
N05BB01 [21604590]
1.9e+00
—
—
—
—
—
—
cases:6.21%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
11
18
166
1747
—
—
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
53027-9 [3041942]
—
1.9e+00
—
—
—
—
—
—
—
cases:4.52%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
8
13
169
1752
—
—
—
—
—
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
2.7e-01
1.8e+00
—
—
—
1.2e+00
6.2e-02
cases:3.95%
controls:3.06%
cases:6.78%
controls:1.13%
—
—
—
—
—
—
cases:4.12%
controls:1.22%
cases:3.90%
controls:3.67%
7
54
170
1711
12
20
165
1745
—
—
—
7
21
163
1706
6
58
148
1522
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.76%
—
—
—
—
—
—
7
12
147
1568
Chronic rhinitis
J31.0 [45572165]
J31.0 [45572165]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.76%
—
—
—
—
—
—
7
12
147
1568
Acute cystitis
N30.0 [45601724]
N30.0 [45601724]
1.3e+00
—
—
—
—
—
1.8e+00
cases:3.95%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:0.89%
7
19
170
1746
—
—
—
—
—
8
14
146
1566
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
—
1.3e+00
—
—
—
1.8e+00
9.7e-01
—
—
cases:2.82%
controls:0.79%
—
—
—
—
—
—
cases:4.71%
controls:0.81%
cases:4.55%
controls:1.77%
—
5
14
172
1751
—
—
—
8
14
162
1713
7
28
147
1552
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
8.1e-01
1.4e+00
—
—
—
1.8e+00
3.9e-01
cases:5.08%
controls:2.32%
cases:2.82%
controls:0.68%
—
—
—
—
—
—
cases:5.29%
controls:0.93%
cases:3.90%
controls:2.66%
9
41
168
1724
5
12
172
1753
—
—
—
9
16
161
1711
6
42
148
1538
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
E11.9 [45561952]
3.4e-01
8.1e-01
—
—
—
1.8e+00
9.2e-01
cases:5.08%
controls:3.68%
cases:3.39%
controls:1.53%
—
—
—
—
—
—
cases:9.41%
controls:1.74%
cases:10.39%
controls:4.43%
9
65
168
1700
6
27
171
1738
—
—
—
16
30
154
1697
16
70
138
1510
norfloxacin; oral
J01MA06 [21603013]
J01MA06 [21603013]
1.8e+00
—
—
—
—
—
1.7e+00
cases:5.08%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:0.82%
9
16
168
1749
—
—
—
—
—
7
13
147
1567
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
1.3e+00
1.8e+00
—
—
—
1.2e+00
3.6e-01
cases:5.65%
controls:1.59%
cases:5.08%
controls:0.91%
—
—
—
—
—
—
cases:4.12%
controls:1.33%
cases:3.25%
controls:2.28%
10
28
167
1737
9
16
168
1749
—
—
—
7
23
163
1704
5
36
149
1544
Orthopedic Surgery
20 [38004465]
20 [38004465]
9.7e-01
5.4e-01
—
—
—
5.3e-01
7.8e-01
cases:19.77%
controls:8.56%
cases:6.78%
controls:4.08%
—
—
—
—
—
—
cases:7.65%
controls:4.63%
cases:27.27%
controls:14.68%
35
151
142
1614
12
72
165
1693
—
—
—
13
80
157
1647
42
232
112
1348
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
4.6e-01
1.7e+00
—
—
—
1.2e+00
6.9e-01
cases:5.65%
controls:3.63%
cases:7.34%
controls:1.36%
—
—
—
—
—
—
cases:6.47%
controls:1.97%
cases:11.69%
controls:6.20%
10
64
167
1701
13
24
164
1741
—
—
—
11
34
159
1693
18
98
136
1482
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
1.9e+00
—
—
—
—
2.0e+00
1.7e+00
cases:2.82%
controls:0.45%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.41%
cases:7.14%
controls:1.33%
5
8
172
1757
—
—
—
—
5
7
165
1720
11
21
143
1559
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.08%
—
—
—
—
—
—
9
17
145
1563
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
—
1.5e+00
—
—
—
1.7e+00
7.4e-01
—
—
cases:3.39%
controls:0.79%
—
—
—
—
—
—
cases:4.71%
controls:0.87%
cases:3.90%
controls:1.90%
—
6
14
171
1751
—
—
—
8
15
162
1712
6
30
148
1550
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
A10AC30 [21600727]
7.0e-01
—
—
—
—
1.5e+00
1.7e+00
cases:2.82%
controls:1.42%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.93%
cases:7.14%
controls:1.39%
5
25
172
1740
—
—
—
—
7
16
163
1711
11
22
143
1558
escitalopram; oral
N06AB10 [21604718]
N06AB10 [21604718]
8.6e-01
1.4e+00
—
—
—
1.7e+00
1.2e+00
cases:5.08%
controls:2.21%
cases:4.52%
controls:1.19%
—
—
—
—
—
—
cases:6.47%
controls:1.27%
cases:7.79%
controls:2.53%
9
39
168
1726
8
21
169
1744
—
—
—
11
22
159
1705
12
40
142
1540
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
4.6e-01
5.6e-01
1.6e+00
1.0e+50
1.4e+00
9.6e-01
6.8e-01
cases:16.38%
controls:10.99%
cases:9.04%
controls:5.38%
cases:3.39%
controls:0.68%
cases:6.21%
controls:0.00%
cases:3.95%
controls:1.02%
cases:13.53%
controls:5.67%
cases:25.32%
controls:14.62%
29
194
148
1571
16
95
161
1670
6
12
171
1753
11
0
166
1765
7
18
170
1744
23
98
147
1629
39
231
115
1349
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
8.4e-01
4.2e-01
—
—
—
8.8e-01
7.8e-01
cases:18.08%
controls:8.67%
cases:4.52%
controls:3.00%
—
—
—
—
—
—
cases:6.47%
controls:2.78%
cases:18.18%
controls:9.24%
32
153
145
1612
8
53
169
1712
—
—
—
11
48
159
1679
28
146
126
1434
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
8.4e-01
4.2e-01
—
—
—
8.8e-01
7.8e-01
cases:18.08%
controls:8.67%
cases:4.52%
controls:3.00%
—
—
—
—
—
—
cases:6.47%
controls:2.78%
cases:18.18%
controls:9.24%
32
153
145
1612
8
53
169
1712
—
—
—
11
48
159
1679
28
146
126
1434
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
8.9e-01
1.9e+00
—
—
—
—
1.6e+00
cases:3.39%
controls:1.42%
cases:2.82%
controls:0.45%
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.52%
6
25
171
1740
5
8
172
1757
—
—
—
—
11
24
143
1556
Dentistry
C5 [903277]
C5 [903277]
7.4e-01
—
—
—
—
—
1.6e+00
cases:3.95%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.27%
7
34
170
1731
—
—
—
—
—
9
20
145
1560
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
6.9e-01
1.5e+00
—
—
—
6.8e-01
4.0e-01
cases:7.91%
controls:4.14%
cases:9.04%
controls:2.15%
—
—
—
—
—
—
cases:4.71%
controls:2.43%
cases:10.39%
controls:7.22%
14
73
163
1692
16
38
161
1727
—
—
—
8
42
162
1685
16
114
138
1466
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
1.3e+00
—
—
—
—
2.0e+00
1.5e+00
cases:3.95%
controls:1.08%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.41%
cases:6.49%
controls:1.52%
7
19
170
1746
—
—
—
—
5
7
165
1720
10
24
144
1556
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
8.8e-01
1.4e+00
—
—
—
1.5e+00
6.9e-01
cases:6.21%
controls:2.66%
cases:3.95%
controls:0.96%
—
—
—
—
—
—
cases:5.88%
controls:1.39%
cases:8.44%
controls:4.43%
11
47
166
1718
7
17
170
1748
—
—
—
10
24
160
1703
13
70
141
1510
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
8.1e-01
—
—
—
—
—
1.5e+00
cases:5.08%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:7.14%
controls:1.71%
9
41
168
1724
—
—
—
—
—
11
27
143
1553
hydroxocobalamin; parenteral
B03BA03 [21601123]
B03BA03 [21601123]
—
1.4e+00
—
—
—
1.2e+00
1.5e+00
—
—
cases:3.95%
controls:1.02%
—
—
—
—
—
—
cases:2.94%
controls:0.87%
cases:5.84%
controls:1.39%
—
7
18
170
1747
—
—
—
5
15
165
1712
9
22
145
1558
hydroxocobalamin
V03AB33 [21605256]
V03AB33 [21605256]
—
1.4e+00
—
—
—
1.2e+00
1.5e+00
—
—
cases:3.95%
controls:1.02%
—
—
—
—
—
—
cases:2.94%
controls:0.87%
cases:5.84%
controls:1.39%
—
7
18
170
1747
—
—
—
5
15
165
1712
9
22
145
1558
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
6.1e-01
1.4e+00
—
—
2.1e+00
4.1e-01
3.9e-01
cases:9.04%
controls:5.10%
cases:11.30%
controls:2.95%
—
—
—
—
cases:2.82%
controls:0.34%
cases:5.29%
controls:3.59%
cases:13.64%
controls:9.68%
16
90
161
1675
20
52
157
1713
—
—
5
6
172
1756
9
62
161
1665
21
153
133
1427
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
9.8e-01
—
—
—
—
—
1.4e+00
cases:3.39%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:1.65%
6
23
171
1742
—
—
—
—
—
10
26
144
1554
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
3.9e-01
1.4e+00
—
—
—
1.2e+00
1.4e+00
cases:3.39%
controls:2.32%
cases:5.08%
controls:1.25%
—
—
—
—
—
—
cases:4.12%
controls:1.22%
cases:11.69%
controls:3.10%
6
41
171
1724
9
22
168
1743
—
—
—
7
21
163
1706
18
49
136
1531
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
—
1.3e+00
—
—
—
1.4e+00
8.8e-01
—
—
cases:6.21%
controls:1.81%
—
—
—
—
—
—
cases:7.65%
controls:1.97%
cases:9.74%
controls:4.30%
—
11
32
166
1733
—
—
—
13
34
157
1693
15
68
139
1512
insulin (human); parenteral
A10AB01 [21600715]
A10AB01 [21600715]
1.4e+00
1.0e+00
—
—
—
—
—
cases:5.65%
controls:1.47%
cases:3.39%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
10
26
167
1739
6
22
171
1743
—
—
—
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
5.8e-01
1.4e+00
—
—
2.1e+00
3.7e-01
4.1e-01
cases:9.04%
controls:5.27%
cases:10.73%
controls:2.95%
—
—
—
—
cases:2.82%
controls:0.34%
cases:5.29%
controls:3.71%
cases:14.29%
controls:9.94%
16
93
161
1672
19
52
158
1713
—
—
5
6
172
1756
9
64
161
1663
22
157
132
1423
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
—
1.3e+00
—
—
—
1.4e+00
1.1e+00
—
—
cases:5.08%
controls:1.47%
—
—
—
—
—
—
cases:6.47%
controls:1.74%
cases:8.44%
controls:3.10%
—
9
26
168
1739
—
—
—
11
30
159
1697
13
49
141
1531
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
5.8e-01
1.4e+00
—
—
2.1e+00
3.7e-01
3.7e-01
cases:9.04%
controls:5.27%
cases:10.73%
controls:3.00%
—
—
—
—
cases:2.82%
controls:0.34%
cases:5.29%
controls:3.71%
cases:13.64%
controls:9.87%
16
93
161
1672
19
53
158
1712
—
—
5
6
172
1756
9
64
161
1663
21
156
133
1424
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
6.3e-01
5.9e-01
—
—
—
7.7e-01
1.3e+00
cases:7.91%
controls:4.36%
cases:2.82%
controls:1.59%
—
—
—
—
—
—
cases:2.94%
controls:1.39%
cases:12.99%
controls:3.73%
14
77
163
1688
5
28
172
1737
—
—
—
5
24
165
1703
20
59
134
1521
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
6.1e-01
8.3e-01
—
—
-1.0e+50
1.2e+00
1.3e+00
cases:3.39%
controls:1.87%
cases:2.82%
controls:1.25%
—
—
—
—
cases:0.00%
controls:0.45%
cases:3.53%
controls:1.10%
cases:8.44%
controls:2.41%
6
33
171
1732
5
22
172
1743
—
—
0
8
177
1754
6
19
164
1708
13
38
141
1542
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
4.1e-01
9.7e-01
—
—
—
1.3e+00
6.5e-01
cases:6.21%
controls:4.19%
cases:4.52%
controls:1.76%
—
—
—
—
—
—
cases:8.82%
controls:2.55%
cases:14.94%
controls:8.42%
11
74
166
1691
8
31
169
1734
—
—
—
15
44
155
1683
23
133
131
1447
Low back symptom/complaint
L03 [2002000628]
L03 [2002000628]
1.1e+00
—
—
—
—
—
1.3e+00
cases:5.65%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:9.74%
controls:2.91%
10
33
167
1732
—
—
—
—
—
15
46
139
1534
Other specified counselling
Z71.8 [45581061]
Z71.8 [45581061]
9.7e-01
—
—
—
—
—
1.3e+00
cases:5.08%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:11.69%
controls:3.61%
9
35
168
1730
—
—
—
—
—
18
57
136
1523
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
7.4e-02
—
—
—
—
1.1e+00
1.2e+00
cases:3.95%
controls:3.68%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.98%
cases:10.39%
controls:3.23%
7
65
170
1700
—
—
—
—
5
17
165
1710
16
51
138
1529
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
Z03.9 [45552062]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.79%
controls:2.41%
—
—
—
—
—
—
12
38
142
1542
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
8.2e-01
1.4e+00
—
—
—
1.4e+00
1.2e+00
cases:10.73%
controls:5.04%
cases:5.08%
controls:1.25%
—
—
—
—
—
—
cases:5.29%
controls:1.39%
cases:13.64%
controls:4.49%
19
89
158
1676
9
22
168
1743
—
—
—
9
24
161
1703
21
71
133
1509
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
1.2e+00
1.1e+00
—
—
—
8.6e-01
6.0e-01
cases:12.43%
controls:4.08%
cases:6.78%
controls:2.32%
—
—
—
—
—
—
cases:5.29%
controls:2.32%
cases:9.09%
controls:5.19%
22
72
155
1693
12
41
165
1724
—
—
—
9
40
161
1687
14
82
140
1498
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
1.2e+00
1.1e+00
—
—
—
8.6e-01
6.0e-01
cases:12.43%
controls:4.08%
cases:6.78%
controls:2.32%
—
—
—
—
—
—
cases:5.29%
controls:2.32%
cases:9.09%
controls:5.19%
22
72
155
1693
12
41
165
1724
—
—
—
9
40
161
1687
14
82
140
1498
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
1.2e+00
1.1e+00
—
—
—
8.6e-01
6.0e-01
cases:12.43%
controls:4.08%
cases:6.78%
controls:2.32%
—
—
—
—
—
—
cases:5.29%
controls:2.32%
cases:9.09%
controls:5.19%
22
72
155
1693
12
41
165
1724
—
—
—
9
40
161
1687
14
82
140
1498
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
1.2e+00
1.1e+00
—
—
—
8.6e-01
6.0e-01
cases:12.43%
controls:4.08%
cases:6.78%
controls:2.32%
—
—
—
—
—
—
cases:5.29%
controls:2.32%
cases:9.09%
controls:5.19%
22
72
155
1693
12
41
165
1724
—
—
—
9
40
161
1687
14
82
140
1498
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
6.5e-01
1.2e+00
—
—
2.1e+00
—
8.8e-02
cases:7.91%
controls:4.31%
cases:7.34%
controls:2.32%
—
—
—
—
cases:2.82%
controls:0.34%
—
—
cases:8.44%
controls:7.78%
14
76
163
1689
13
41
164
1724
—
—
5
6
172
1756
—
13
123
141
1457
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
2.3e-01
1.2e+00
—
—
—
7.8e-01
2.9e-01
cases:9.04%
controls:7.31%
cases:8.47%
controls:2.83%
—
—
—
—
—
—
cases:6.47%
controls:3.07%
cases:13.64%
controls:10.57%
16
129
161
1636
15
50
162
1715
—
—
—
11
53
159
1674
21
167
133
1413
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
1.1e+00
1.0e+00
—
—
—
1.3e+00
7.7e-01
cases:9.60%
controls:3.29%
cases:4.52%
controls:1.64%
—
—
—
—
—
—
cases:5.88%
controls:1.62%
cases:11.04%
controls:5.44%
17
58
160
1707
8
29
169
1736
—
—
—
10
28
160
1699
17
86
137
1494
trimethoprim; oral, parenteral
J01EA01 [21602931]
J01EA01 [21602931]
1.1e+00
1.1e+00
—
—
—
—
8.5e-01
cases:9.60%
controls:3.29%
cases:3.95%
controls:1.42%
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.11%
17
58
160
1707
7
25
170
1740
—
—
—
—
14
65
140
1515
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
8.8e-01
9.0e-01
—
—
—
1.3e+00
1.1e+00
cases:6.21%
controls:2.66%
cases:3.95%
controls:1.64%
—
—
—
—
—
—
cases:5.29%
controls:1.56%
cases:10.39%
controls:3.73%
11
47
166
1718
7
29
170
1736
—
—
—
9
27
161
1700
16
59
138
1521
tizanidine; oral
M03BX02 [21604116]
M03BX02 [21604116]
6.0e-01
1.1e+00
—
—
—
8.9e-01
4.2e-01
cases:18.64%
controls:11.22%
cases:11.30%
controls:4.25%
—
—
—
—
—
—
cases:7.65%
controls:3.30%
cases:17.53%
controls:12.28%
33
198
144
1567
20
75
157
1690
—
—
—
13
57
157
1670
27
194
127
1386
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
6.3e-01
1.2e+00
—
—
—
—
1.0e+00
cases:7.91%
controls:4.36%
cases:3.95%
controls:1.25%
—
—
—
—
—
—
—
—
cases:11.04%
controls:4.18%
14
77
163
1688
7
22
170
1743
—
—
—
—
17
66
137
1514
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.7e-01
cases:14.69%
controls:5.72%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.96%
26
101
151
1664
6
36
171
1729
—
—
0
6
177
1756
—
15
110
139
1470
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.7e-01
cases:14.69%
controls:5.72%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.96%
26
101
151
1664
6
36
171
1729
—
—
0
6
177
1756
—
15
110
139
1470
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.8e-01
cases:14.12%
controls:5.50%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.90%
25
97
152
1668
6
36
171
1729
—
—
0
6
177
1756
—
15
109
139
1471
hydrocortisone butyrate
D07AB02 [21602106]
D07AB02 [21602106]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.8e-01
cases:14.12%
controls:5.50%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.90%
25
97
152
1668
6
36
171
1729
—
—
0
6
177
1756
—
15
109
139
1471
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.8e-01
cases:14.12%
controls:5.50%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.90%
25
97
152
1668
6
36
171
1729
—
—
0
6
177
1756
—
15
109
139
1471
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
1.0e+00
5.2e-01
—
—
-1.0e+50
—
3.8e-01
cases:14.12%
controls:5.50%
cases:3.39%
controls:2.04%
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:9.74%
controls:6.90%
25
97
152
1668
6
36
171
1729
—
—
0
6
177
1756
—
15
109
139
1471
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
M01AE03 [21603969]
1.0e+00
2.5e-01
—
—
—
6.3e-01
5.0e-01
cases:12.43%
controls:4.82%
cases:2.82%
controls:2.21%
—
—
—
—
—
—
cases:3.53%
controls:1.91%
cases:7.79%
controls:4.87%
22
85
155
1680
5
39
172
1726
—
—
—
6
33
164
1694
12
77
142
1503
hydrocortisone
S02BA01 [21605166]
S02BA01 [21605166]
1.0e+00
7.1e-01
—
—
-1.0e+50
—
5.3e-01
cases:12.43%
controls:4.93%
cases:3.39%
controls:1.70%
—
—
—
—
cases:0.00%
controls:0.28%
—
—
cases:9.09%
controls:5.57%
22
87
155
1678
6
30
171
1735
—
—
0
5
177
1757
—
14
88
140
1492
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
N04AB02 [21604458]
8.3e-01
—
—
—
—
1.1e+00
1.0e+00
cases:9.60%
controls:4.42%
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.80%
cases:12.34%
controls:4.94%
17
78
160
1687
—
—
—
—
9
31
161
1696
19
78
135
1502
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
M03BC01 [21604112]
8.3e-01
—
—
—
—
1.1e+00
1.0e+00
cases:9.60%
controls:4.42%
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.80%
cases:12.34%
controls:4.94%
17
78
160
1687
—
—
—
—
9
31
161
1696
19
78
135
1502
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
C01DA02 [21600317]
9.4e-01
8.1e-01
—
—
-1.0e+50
8.6e-01
3.7e-01
cases:10.73%
controls:4.48%
cases:5.08%
controls:2.32%
—
—
—
—
cases:0.00%
controls:0.40%
cases:6.47%
controls:2.84%
cases:6.49%
controls:4.56%
19
79
158
1686
9
41
168
1724
—
—
0
7
177
1755
11
49
159
1678
10
72
144
1508
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
9.4e-01
5.9e-01
—
—
-1.0e+50
3.7e-01
4.7e-01
cases:14.69%
controls:6.29%
cases:5.08%
controls:2.89%
—
—
—
—
cases:0.00%
controls:0.62%
cases:4.71%
controls:3.30%
cases:10.39%
controls:6.77%
26
111
151
1654
9
51
168
1714
—
—
0
11
177
1751
8
57
162
1670
16
107
138
1473
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
5.0e-01
1.1e+00
—
—
-1.0e+50
9.4e-01
9.4e-01
cases:9.60%
controls:6.06%
cases:6.78%
controls:2.32%
—
—
—
—
cases:0.00%
controls:0.40%
cases:5.88%
controls:2.37%
cases:13.64%
controls:5.82%
17
107
160
1658
12
41
165
1724
—
—
0
7
177
1755
10
41
160
1686
21
92
133
1488
atorvastatin; oral
C10AA05 [21601860]
C10AA05 [21601860]
5.1e-01
7.4e-01
—
—
—
8.7e-01
7.0e-01
cases:10.17%
controls:6.35%
cases:11.30%
controls:5.72%
—
—
—
—
—
—
cases:12.94%
controls:5.85%
cases:17.53%
controls:9.56%
18
112
159
1653
20
101
157
1664
—
—
—
22
101
148
1626
27
151
127
1429
phenoxymethylpenicillin; oral
J01CE02 [21602842]
J01CE02 [21602842]
5.9e-01
3.2e-01
—
—
—
-2.7e-01
8.1e-01
cases:18.08%
controls:10.93%
cases:3.95%
controls:2.89%
—
—
—
—
—
—
cases:2.94%
controls:3.82%
cases:23.38%
controls:11.96%
32
193
145
1572
7
51
170
1714
—
—
—
5
66
165
1661
36
189
118
1391
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
J01CE10 [21602850]
5.9e-01
3.2e-01
—
—
—
-2.7e-01
8.1e-01
cases:18.08%
controls:10.93%
cases:3.95%
controls:2.89%
—
—
—
—
—
—
cases:2.94%
controls:3.82%
cases:23.38%
controls:11.96%
32
193
145
1572
7
51
170
1714
—
—
—
5
66
165
1661
36
189
118
1391
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
4.3e-01
5.5e-01
1.9e+00
—
—
7.4e-01
7.7e-01
cases:14.12%
controls:9.69%
cases:6.78%
controls:4.02%
cases:2.82%
controls:0.45%
—
—
—
—
cases:8.82%
controls:4.40%
cases:25.97%
controls:13.99%
25
171
152
1594
12
71
165
1694
5
8
172
1757
—
—
15
76
155
1651
40
221
114
1359
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
M01AB05 [21603945]
7.5e-01
6.4e-01
—
—
—
6.2e-02
3.3e-01
cases:21.47%
controls:11.39%
cases:7.34%
controls:4.02%
—
—
—
—
—
—
cases:4.12%
controls:3.88%
cases:18.83%
controls:14.30%
38
201
139
1564
13
71
164
1694
—
—
—
7
67
163
1660
29
226
125
1354
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
SDE04 [2001310352]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
170
1722
—
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
SPAT1306 [2001700407]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:1.96%
—
—
—
—
—
—
6
31
148
1549
Human epididymis protein 4 [Moles/volume] in Serum or Plasma
55180-4 [40758310]
55180-4 [40758310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
177
1758
—
—
—
—
—
—
Handing over of treatment supplies
SPAT1262 [2001700363]
SPAT1262 [2001700363]
2.0e-01
—
—
—
—
—
3.7e-01
cases:2.82%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:4.11%
5
41
172
1724
—
—
—
—
—
9
65
145
1515
Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]
K80.0 [45586735]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
Differential panel - Synovial fluid
29582-4 [3021788]
29582-4 [3021788]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
tafluprost
S01EE05 [21603714]
S01EE05 [21603714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
177
1759
—
—
—
—
—
—
Memory disturbance
P20 [2002000816]
P20 [2002000816]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
8
170
1719
—
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
Z76.9 [45609967]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
177
1760
—
—
—
—
—
—
perindopril and amlodipine
C09BB04 [21601818]
C09BB04 [21601818]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
6
177
1759
0
6
177
1759
—
—
—
0
6
170
1721
—
insulin aspart; parenteral
A10AB05 [21600719]
A10AB05 [21600719]
5.5e-01
5.5e-01
—
—
—
3.9e-01
4.2e-01
cases:3.95%
controls:2.32%
cases:3.95%
controls:2.32%
—
—
—
—
—
—
cases:4.12%
controls:2.84%
cases:5.19%
controls:3.48%
7
41
170
1724
7
41
170
1724
—
—
—
7
49
163
1678
8
55
146
1525
clobetasol
D07AD01 [21602141]
D07AD01 [21602141]
1.3e+00
—
—
—
—
1.6e+00
4.2e-01
cases:5.65%
controls:1.53%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.64%
cases:3.90%
controls:2.59%
10
27
167
1738
—
—
—
—
5
11
165
1716
6
41
148
1539
Routine postpartum follow-up
Z39.2 [45547306]
Z39.2 [45547306]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
8
177
1757
0
6
177
1759
—
—
—
—
—
Amoebic infection of other sites
A06.8 [45556889]
A06.8 [45556889]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:2.82%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
172
1765
—
—
—
Sinusitis acute/chronic
R75 [2002000943]
R75 [2002000943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
7
154
1573
Antenatal screening for malformation
717800004 [36713462]
717800004 [36713462]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.81%
cases:0.00%
controls:0.40%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
0
32
177
1733
0
7
177
1758
—
—
—
0
16
170
1711
—
Asthma
J45 [45596282]
J45 [45596282]
1.0e+00
—
—
—
—
—
8.2e-01
cases:3.95%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:1.46%
7
26
170
1739
—
—
—
—
—
5
23
149
1557
Eyelid symptom/complaint
F16 [2002000407]
F16 [2002000407]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
154
1574
erythromycin; oral, parenteral
J01FA01 [21602970]
J01FA01 [21602970]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
177
1755
—
—
—
—
—
—
General symptom/complaint other
A29 [2002000163]
A29 [2002000163]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.55%
controls:1.39%
—
—
—
—
—
—
7
22
147
1558
fusidic acid; ointment
D06AX01 [21602062]
D06AX01 [21602062]
—
—
—
—
—
—
2.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:3.16%
—
—
—
—
—
—
6
50
148
1530
Rosacea, unspecified
L71.9 [45548204]
L71.9 [45548204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
K80.2 [45552951]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
14
154
1566
Neurosurgery
14 [38004459]
14 [38004459]
5.2e-01
—
—
—
—
-1.0e+50
—
cases:2.82%
controls:1.70%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
5
30
172
1735
—
—
—
—
0
5
170
1722
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.25%
controls:0.95%
—
—
—
—
—
—
5
15
149
1565
Preventive oral health care, short
SCA01 [2001310302]
SCA01 [2001310302]
3.1e-01
—
—
—
—
—
3.5e-01
cases:4.52%
controls:3.34%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:4.18%
8
59
169
1706
—
—
—
—
—
9
66
145
1514
acrivastine; oral
R06AX18 [21603518]
R06AX18 [21603518]
7.0e-01
—
—
—
—
—
6.9e-01
cases:10.17%
controls:5.33%
—
—
—
—
—
—
—
—
—
—
cases:12.34%
controls:6.58%
18
94
159
1671
—
—
—
—
—
19
104
135
1476
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
8.7e-01
—
—
—
—
—
8.7e-01
cases:3.95%
controls:1.70%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:2.53%
7
30
170
1735
—
—
—
—
—
9
40
145
1540
olodaterol and tiotropium bromide
R03AL06 [1588644]
R03AL06 [1588644]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
Dental calculus supragingival
K03.64 [2000502689]
K03.64 [2000502689]
5.5e-01
—
—
—
—
1.2e+00
4.5e-01
cases:4.52%
controls:2.66%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.87%
cases:6.49%
controls:4.24%
8
47
169
1718
—
—
—
—
5
15
165
1712
10
67
144
1513
Benign neoplasm: Skin of eyelid, including canthus
D23.1 [45600585]
D23.1 [45600585]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
Vertigo/dizziness
N17 [2002000728]
N17 [2002000728]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.90%
controls:1.39%
—
—
—
—
—
—
6
22
148
1558
Sprain and strain involving (fibular)(tibial) collateral ligament of knee
S83.4 [45550630]
S83.4 [45550630]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
CK2X4 [2001301456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
0
5
177
1760
—
—
—
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
MA1AE [2001306827]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
15
177
1750
—
—
—
—
0
6
170
1721
—
Contusion of thorax
S20.2 [45597402]
S20.2 [45597402]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
154
1574
Presence of external hearing-aid
Z97.4 [45542504]
Z97.4 [45542504]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
177
1758
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:3.25%
controls:1.08%
—
—
—
—
—
0
7
170
1720
5
17
149
1563
Palmar fascial fibromatosis [Dupuytren]
M72.0 [45543681]
M72.0 [45543681]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
154
1575
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
49
11.38
37.53
3.3
1.6
—
—
—
0
0
46
93
6.21
22.97
2.3
1.5
—
—
—
0
0
35
54
7.72
22.61
1.5
1.6
1.21
6.26
ug/l
0.46
28
46
68
228
4.09
18.09
3.2
1.8
—
—
—
0
0
55
166
4.26
16.77
2.9
1.7
—
—
—
0
0
53
161
4.18
15.96
3.1
1.8
—
—
—
0
0
66
239
3.70
15.41
3.8
2.3
2.19
2.30
g/l
0.65
60
218
51
159
4.02
14.73
7.9
2.8
1.51
1.86
mmol/l
0.30
46
137
126
706
3.33
14.04
8.8
4.1
33.80
36.19
g/l
3.96
120
667
32
73
5.07
13.69
2.5
1.7
—
—
—
0
0
68
269
3.38
13.62
3.8
2.3
9.77
13.39
umol/l
3.17
62
246
23
39
6.57
13.40
1.8
1.5
—
—
—
0
0
110
592
3.04
12.73
5.7
2.9
—
—
—
0
0
70
293
3.20
12.64
4.4
3.5
470.26
392.39
ng/l
0.10
57
221
95
474
3.01
12.58
5.5
2.9
0.27
0.28
e6/l
0.02
64
333
140
879
3.25
12.01
11.5
5.9
10.19
11.44
umol/l
1.30
135
829
49
170
3.54
11.91
13.8
6.2
0.73
0.85
mmol/l
0.07
39
144
133
818
3.09
11.70
17.2
5.7
1.21
1.21
mmol/l
0.37
124
700
67
287
3.06
11.47
4.7
2.7
1.10
0.86
e6/l
0.21
32
149
63
262
3.10
11.34
4.8
2.8
4.12
1.79
e6/l
0.47
26
126
41
131
3.72
11.24
4.2
2.6
64.52
67.04
g/l
1.51
36
126
76
364
2.81
10.46
2.7
1.7
1.43
1.21
mg/l
0.24
65
287
22
46
5.28
10.30
1.5
1.3
—
—
—
0
0
142
956
2.92
9.67
11.3
4.1
7.03
6.61
mmol/l
1.14
136
899
19
37
5.59
9.58
2.5
1.5
—
—
—
0
0
78
393
2.67
9.57
4.6
2.9
346.69
336.87
umol/l
0.35
67
339
21
46
5.01
9.31
2.2
4.2
1.30
3.03
ratio
0.70
11
24
90
492
2.58
9.28
2.3
1.7
17.00
21.47
nmol/l
2.50
80
401
167
1250
3.78
9.07
14.3
7.2
75.76
79.12
u/l
0.66
160
1169
13
7
19.81
9.07
2.2
1.3
—
—
—
0
0
81
425
2.58
9.05
3.4
2.0
2.70
2.81
mg/l
0.20
74
360
92
513
2.54
9.04
3.9
2.2
57.13
76.54
u/l
0.88
82
467
31
96
3.66
8.80
7.2
2.3
1.67
1.87
mmol/l
0.10
24
75
13
8
17.31
8.68
2.2
1.4
—
—
—
0
0
114
722
2.45
8.24
3.5
2.4
76.97
76.86
nmol/l
0.02
106
633
115
732
2.45
8.21
3.0
2.1
98.88
94.59
pmol/l
0.43
69
363
118
760
2.46
8.20
5.1
3.0
116.15
109.66
ug/l
0.13
110
706
137
945
2.61
8.20
15.8
9.6
4.29
3.99
e9/l
0.60
120
834
58
271
2.64
8.09
2.1
1.7
897.14
1187.73
nmol/l
1.87
43
199
21
52
4.42
8.04
2.4
4.4
51.40
152.34
mg/l
0.44
21
46
21
52
4.42
8.04
2.4
4.4
113.98
28.52
mg/l
0.56
21
46
89
510
2.40
8.00
4.4
3.2
1476.51
1264.97
ng/l
0.31
78
431
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
30
6.91
7.95
4.1
2.2
0.37
0.32
iu/ml
—
9
16
29
94
3.46
7.67
5.4
2.4
128.28
128.73
g/l
0.03
29
89
51
229
2.68
7.66
15.6
5.6
104.41
104.06
mmol/l
0.22
51
229
27
86
3.49
7.32
1.9
1.3
—
—
—
0
0
19
34
6.09
7.29
2.4
1.5
—
—
—
0
0
31
109
3.20
7.20
5.9
3.1
103.37
80.66
ng/l
0.82
24
96
14
17
8.79
6.96
1.9
1.6
—
—
—
0
0
15
21
7.65
6.85
2.4
1.9
—
—
—
0
0
14
18
8.30
6.74
2.4
1.4
—
—
—
0
0
38
156
2.79
6.72
3.4
2.1
32.85
32.35
u/l
0.04
33
128
70
386
2.29
6.62
4.1
2.2
—
—
—
0
0
18
46
4.22
6.61
2.0
1.3
272.23
309.64
ug/g
0.31
13
30
126
887
2.25
6.44
6.5
3.8
0.00
0.02
estimate
0.50
21
180
19
52
3.95
6.38
1.5
1.1
—
—
—
0
0
9
5
18.79
6.32
1.4
2.0
—
—
—
0
0
9
5
18.79
6.32
1.4
2.0
—
—
—
0
0
40
174
2.65
6.31
3.3
2.7
8.06
6.34
umol/l
0.42
33
155
124
872
2.21
6.29
6.5
3.7
0.00
0.00
estimate
-0.00
23
194
99
638
2.15
6.28
5.9
3.8
43.69
46.69
ng/l
0.06
76
458
92
581
2.13
6.10
4.9
3.1
2.32
2.36
mmol/l
2.28
85
527
124
879
2.18
6.07
6.5
3.8
0.00
8.29
estimate
0.50
23
196
18
51
3.79
5.76
1.6
1.1
—
—
—
0
0
70
405
2.15
5.75
1.5
1.3
1.18
1.53
u/ml
0.16
14
103
12
16
7.92
5.73
2.3
2.0
—
—
—
0
0
131
962
2.16
5.68
3.8
3.0
—
—
—
0
0
12
17
7.45
5.53
2.3
1.9
—
—
—
0
0
12
17
7.45
5.53
2.3
1.9
—
—
—
0
0
156
1237
2.46
5.50
7.2
4.2
17.72
11.26
mm/h
3.24
148
1136
18
53
3.65
5.46
4.9
2.0
23.91
24.96
mmol/l
0.43
18
53
24
87
3.01
5.27
2.5
2.2
1.10
1.22
%
0.30
24
87
5
0
+∞
5.23
4.6
0.0
—
—
—
0
0
11
15
7.71
5.22
2.0
1.3
—
—
—
0
0
18
56
3.45
5.04
3.4
2.8
—
—
—
0
0
11
16
7.22
5.03
2.4
2.0
—
—
—
0
0
11
17
6.79
4.85
2.4
1.9
—
—
—
0
0
11
17
6.79
4.85
2.4
1.9
—
—
—
0
0
14
30
4.95
4.79
2.1
1.5
—
—
—
0
0
7
5
14.46
4.61
1.6
2.0
—
—
—
0
0
7
5
14.46
4.61
1.6
2.0
—
—
—
0
0
32
145
2.45
4.60
2.7
2.3
8.66
6.63
ug/l
0.32
27
126
137
1072
2.00
4.38
5.2
3.1
60.60
43.97
u/l
0.79
131
1006
8
9
9.21
4.32
1.6
1.9
16.88
11.33
u/l
—
8
9
13
30
4.57
4.21
1.8
1.2
—
—
—
0
0
104
752
1.85
4.15
5.0
2.6
—
—
estimate
—
0
0
20
75
2.86
4.14
1.3
1.4
—
—
—
0
0
12
26
4.85
4.13
1.8
1.1
438.57
320.78
u/ml
—
7
9
8
10
8.29
4.10
1.6
1.6
—
—
—
0
0
12
27
4.67
4.01
2.3
1.3
—
—
—
0
0
37
191
2.16
3.93
1.8
1.6
1.66
1.44
%
0.72
31
161
17
60
3.01
3.91
1.4
2.7
0.00
0.00
g/l
-0.00
17
53
12
28
4.50
3.89
2.1
1.5
—
—
—
0
0
57
347
1.92
3.86
3.2
2.7
2.41
2.45
mmol/l
1.71
52
313
7
8
9.03
3.80
1.0
1.3
—
—
—
0
0
15
50
3.17
3.78
3.0
1.8
—
—
—
0
0
24
104
2.50
3.78
22.5
7.6
0.62
0.66
%
0.18
24
104
13
34
4.03
3.77
2.2
1.4
—
—
—
0
0
19
73
2.78
3.77
1.6
1.7
6.90
6.94
iu/ml
—
6
17
52
310
1.93
3.73
1.2
1.3
29.71
26.34
iu/ml
—
7
98
33
169
2.15
3.56
2.5
1.9
341.93
380.39
nmol/l
0.56
27
157
24
108
2.40
3.49
22.3
7.4
1.43
1.40
%
0.04
24
108
15
53
2.99
3.44
9.4
2.4
8.65
8.47
kpa
0.15
15
53
9
18
5.19
3.41
1.9
1.7
—
—
—
0
0
8
14
5.91
3.37
2.8
1.4
0.61
0.59
e9/l
—
8
14
178
1595
2.84
3.27
39.9
13.7
26.77
22.96
mg/l
0.81
156
1297
148
1243
1.86
3.16
5.1
4.4
14.94
14.83
pmol/l
0.20
136
1110
169
1487
2.24
3.12
7.0
5.4
1.95
1.91
mu/l
0.15
161
1332
12
36
3.49
3.08
3.7
2.6
7.66
7.10
pmol/l
0.14
12
36
6
8
7.70
3.07
2.5
3.5
0.63
0.61
mmol/l
—
6
8
13
46
2.96
2.98
1.7
1.3
—
—
—
0
0
8
17
4.86
2.95
3.5
2.0
—
—
—
0
0
45
277
1.82
2.88
1.2
1.3
2.62
9.38
u/ml
1.61
13
113
14
53
2.77
2.86
2.7
1.9
—
—
—
0
0
13
48
2.83
2.78
3.4
2.5
196.46
191.90
%
0.05
13
48
11
34
3.37
2.77
3.0
2.5
14.80
16.11
%
0.66
11
34
5
6
8.51
2.76
3.6
1.3
—
—
—
0
0
5
6
8.51
2.76
2.6
2.0
—
—
—
0
0
5
6
8.51
2.76
1.2
1.5
—
—
—
0
0
7
14
5.15
2.75
3.9
2.2
—
—
—
0
0
50
322
1.75
2.74
2.2
1.7
460.93
44656924.96
pmol/l
0.50
45
262
76
552
1.63
2.65
5.8
3.8
14.10
8.56
mg/mmol
0.57
56
335
9
25
3.73
2.61
2.8
5.1
—
—
—
0
0
9
25
3.73
2.61
1.9
1.6
—
—
—
0
0
5
7
7.30
2.56
1.6
1.6
—
—
—
0
0
5
7
7.30
2.56
1.6
1.6
—
—
—
0
0
5
7
7.30
2.56
1.6
1.7
—
—
—
0
0
6
11
5.59
2.56
2.3
1.3
—
—
—
0
0
6
11
5.59
2.56
1.7
1.3
10.67
8.91
u/l
—
6
11
6
12
5.12
2.42
1.8
1.8
75.00
102.25
%
—
6
12
10
33
3.14
2.39
2.5
1.5
—
—
—
0
0
5
8
6.38
2.38
5.6
6.3
776.80
995.13
u/ml
—
5
8
7
17
4.23
2.38
1.0
1.2
—
—
—
0
0
11
40
2.86
2.31
8.3
2.1
—
—
—
0
0
19
94
2.13
2.25
1.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
9
5.67
2.22
1.0
1.3
—
—
—
0
0
5
10
5.10
2.08
1.2
3.1
62.40
254.40
nmol/l
—
5
10
6
15
4.09
2.05
1.0
1.1
—
—
—
0
0
176
1624
2.14
2.04
46.5
16.2
139.01
139.73
mmol/l
3.28
176
1589
176
1624
2.14
2.04
47.0
16.4
3.96
3.97
mmol/l
0.14
176
1587
8
26
3.17
2.04
1.3
1.5
—
—
—
0
0
8
26
3.17
2.04
1.3
1.1
—
—
—
0
0
8
26
3.17
2.04
1.3
1.5
—
—
—
0
0
27
159
1.81
1.98
3.3
2.2
—
—
—
0
0
6
16
3.84
1.95
1.2
1.1
—
—
—
0
0
7
22
3.26
1.90
1.1
1.5
—
—
—
0
0
5
12
4.25
1.83
3.6
1.6
—
—
—
0
0
7
23
3.12
1.81
1.3
1.2
—
—
—
0
0
11
47
2.42
1.81
1.3
1.3
—
—
—
0
0
6
18
3.41
1.76
1.0
1.2
—
—
—
0
0
163
1489
1.67
1.67
5.2
4.3
1.36
1.27
mmol/l
0.77
151
1356
84
676
1.43
1.64
7.2
3.7
0.00
0.01
estimate
0.50
18
167
5
14
3.64
1.62
1.6
1.8
—
—
—
0
0
5
14
3.64
1.62
1.6
1.8
—
—
—
0
0
5
14
3.64
1.62
1.6
1.8
—
—
—
0
0
5
14
3.64
1.62
1.8
1.4
271.80
245.91
u/l
—
5
14
7
27
2.65
1.53
1.0
1.3
—
—
—
0
0
166
1534
1.65
1.49
34.9
14.4
78.21
80.86
ml/min/173m2
0.70
154
1414
64
498
1.43
1.48
6.8
4.0
0.00
0.00
estimate
-0.00
23
174
7
28
2.56
1.46
1.0
1.3
—
—
—
0
0
5
16
3.18
1.44
1.0
1.1
—
—
—
0
0
6
22
2.78
1.44
1.0
1.3
—
—
—
0
0
26
169
1.62
1.38
6.4
3.0
—
—
—
0
0
5
17
2.99
1.36
1.4
1.4
—
—
—
0
0
62
486
1.41
1.36
6.1
3.3
0.00
0.01
estimate
0.50
22
157
163
1510
1.56
1.32
8.8
6.4
40.79
39.15
mmol/mol
1.20
156
1412
178
1686
1.88
1.31
47.5
18.5
87.74
76.19
umol/l
2.19
178
1662
6
24
2.55
1.31
1.0
1.3
—
—
—
0
0
6
24
2.55
1.31
1.2
1.1
—
—
—
0
0
6
24
2.55
1.31
1.0
1.3
—
—
—
0
0
6
24
2.55
1.31
1.0
1.3
—
—
—
0
0
5
18
2.82
1.29
1.4
1.2
—
—
—
0
0
5
18
2.82
1.29
1.4
1.6
—
—
—
0
0
14
77
1.88
1.29
4.8
2.0
—
—
—
0
0
167
1559
1.59
1.26
6.1
5.2
4.30
4.61
mmol/l
3.27
157
1446
5
19
2.67
1.22
1.8
2.3
1.24
1.20
mmol/l
—
5
19
5
19
2.67
1.22
1.8
2.3
110.20
105.42
mmol/l
—
5
19
16
94
1.77
1.22
4.9
2.0
—
—
—
0
0
166
1552
1.55
1.20
6.0
5.1
1.37
1.47
mmol/l
1.98
154
1425
169
1587
1.59
1.18
7.0
5.9
2.51
2.69
mmol/l
1.96
163
1463
26
176
1.55
1.18
3.7
2.2
—
—
—
0
0
50
387
1.40
1.17
6.3
3.9
1.02
1.02
kg/l
0.14
37
247
8
39
2.10
1.17
1.1
1.3
—
—
—
0
0
5
20
2.54
1.16
1.2
1.1
—
—
—
0
0
41
308
1.42
1.13
1.7
1.6
—
—
—
0
0
5
21
2.42
1.09
1.2
1.1
101.00
109.00
%
—
5
21
81
697
1.28
0.91
2.2
1.9
1.38
1.36
mmol/l
0.06
67
573
8
48
1.70
0.80
1.5
2.2
—
—
—
0
0
164
1560
1.37
0.76
6.2
5.1
6.21
5.90
mmol/l
1.43
152
1420
5
25
2.03
0.73
2.8
1.3
0.32
0.31
nmol/l
—
5
16
6
39
1.56
0.53
1.8
1.5
—
—
—
0
0
13
92
1.44
0.52
8.6
3.0
1.02
1.02
ratio
0.38
13
87
17
127
1.37
0.51
2.8
3.0
50.67
64.24
ml/min/173m2
—
9
50
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
5
36
1.40
0.38
1.0
1.1
—
—
—
0
0
23
194
1.21
0.31
16.3
7.4
—
—
—
0
0
11
141
0.77
0.30
1.5
1.4
—
—
—
0
0
24
209
1.17
0.24
4.3
4.7
29.37
31.99
%
0.62
19
126
21
240
0.86
0.22
1.5
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
3.3
—
1.00
—
0
11
0
10
0.00
0.21
0.0
1.3
—
223.33
—
0
10
45
428
1.07
0.11
3.4
4.7
21.44
21.73
%
0.03
16
208
5
47
1.07
0.09
1.4
1.4
—
—
—
0
0
33
321
1.03
0.02
2.4
3.3
0.55
0.75
ug/l
1.15
26
209
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
41.09
—
0
8
0
8
0.00
0.00
0.0
1.1
—
92.89
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.22
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: AB1_SEPSIS_PARAS_IMPL – Implicit parasitic Sepsis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).